Sign our letter to the Prime Minister | PatientsCann UK® Skip to content Medical Cannabis Awareness WeekOpen letter It’s been legal for 8 years. Stop the hate and fear. We are writing to the Prime Minister to ask him to stand with prescribed medical cannabis patients. Add your name and postcode, and we will hand your signature in to 10 Downing Street on Saturday 7 November. PatientsCann UK®Hand-in: Saturday 7 November 202610 Downing Street, London Add your name Read the letter Download PDF Who it is toThe Rt Hon Andy Burnham MP, Prime Minister What we needYour name and postcode. That is all. When we hand it inSaturday 7 November, at 10 Downing Street The letter The Rt Hon Andy Burnham MPPrime Minister10 Downing StreetLondonSW1A 2AA It’s Been Legal for 8 Years: Stop the Hate and Fear Dear Prime Minister, This week is Medical Cannabis Awareness Week, and we are asking you to stand with prescribed medical cannabis patients across the United Kingdom. Medical cannabis became legal to prescribe on 1 November 2018. Eight years later, legality has still not delivered equality, understanding or meaningful access. Medical Cannabis Awareness Week exists because patients continue to have to explain, defend and fight for recognition of their medicine. Patients are still treated with criminality for taking medication prescribed by specialist clinicians. They are challenged at work, questioned in public, denied access to pubs, venues and community spaces, separated from their medication and repeatedly forced to prove that they are patients, not criminals. The discrimination reaches into every part of life. Patients face workplace drug-testing and zero-tolerance policies that may fail to distinguish prescribed treatment from illicit use. Some fear complaints, eviction or homelessness because landlords and housing providers misunderstand their medication. Others are refused entry to pubs, social clubs, entertainment venues, sporting events and the very community spaces that should protect people from loneliness and isolation. They face uncertainty while driving, travelling and interacting with the police. They encounter misunderstanding within hospitals, care homes and other health and social-care settings. Some are unable to administer their prescribed treatment or find that lawful medication is viewed as a behavioural, safeguarding or illicit-drug concern rather than part of their healthcare. For people who rely on adult social care, the consequences can be especially profound. They may depend on carers, supported accommodation, residential services or local authorities to respect and facilitate their prescribed treatment. Poor understanding can interfere not only with medication, but with a person’s autonomy, dignity, independence and ability to remain connected to their community. You have spoken powerfully about creating a social-care system founded on dignity, security and support. You have also emphasised the importance of listening to lived experience and bringing government departments together rather than allowing people to be passed around a fragmented system. Medical cannabis patients need those same principles applied to them. Too many people who might benefit from treatment remain unable to access it through the NHS. They must pay privately or go without. This creates a cruel divide between those who can afford lawful treatment and those who cannot, while patients already prescribed privately may find that other parts of the health and care system do not understand or properly recognise their prescriptions. Behind every failure is a person. A worker afraid to disclose their prescription. A tenant frightened that misunderstanding could cost them their home. A social-care user whose treatment is questioned or disrupted by those responsible for supporting them. A patient turned away from a pub, social club or community venue and cut off from ordinary social life. A driver anxious that lawful medication may be misunderstood at the roadside. A disabled football supporter uncertain whether they will be admitted with their medicine. A family paying privately because meaningful NHS access remains beyond reach. A patient who has followed the law but is still made to feel ashamed. You recently argued that it was unfair for football supporters to be singled out and prevented from consuming alcohol in sight of the pitch when supporters of other sports are treated differently. You called for outdated assumptions to be reconsidered and described the unequal treatment of football supporters as discriminatory. We urge you to apply that same principle of fairness to patients. Alcohol is a recreational product. Medical cannabis is prescribed medication. If football supporters’ ability to drink alcohol deserves national debate, disabled patients being denied entry, prevented from carrying medication or forced to choose between treatment and participation demands attention too. The same principle applies to pubs and community spaces. These are not merely commercial venues. They are places where friendships are maintained, loneliness is reduced and communities come together. A patient should not be excluded from them because staff or security do not understand a lawful prescription. Nor should a person’s medication contribute to housing insecurity or homelessness. Nobody should fear losing their accommodation because a landlord, housing officer or support provider mistakes prescribed treatment for illicit drug use. These are not separate problems. They are connected expressions of the same failure to recognise patients as patients. The person challenged at a football turnstile may already have faced discrimination from an employer, landlord, police officer, healthcare professional, social-care provider or pub door staff. Patients should not have to renegotiate the legitimacy of their medication in every workplace, home, hospital, care setting, stadium and community space they enter. The consequences are emotional as well as practical. People withdraw from employment, healthcare, and community life. Some alter or interrupt their treatment because they fear confrontation. Others experience financial hardship, housing insecurity, worsening health, damaged relationships and profound isolation. Enough is enough. It’s Been Legal for 8 Years: Stop the Hate and Fear. We are urging you to: Publicly recognise medical cannabis patients as patients, acknowledging the stigma, exclusion, financial pressure and institutional barriers they continue to face. Meet medical cannabis patient groups and people with direct lived experience, including patients affected by barriers in employment, housing, homelessness services, social care, healthcare, driving, policing, sport, pubs

<p>The post Sign The Letter No10 first appeared on PatientsCann UK®.</p>

Our plan for Medical Cannabis Awareness Week 2026 | PatientsCann UK® Skip to content MCAW 20261 to 7 NovemberEight years of legal prescribing Our plan for Medical Cannabis Awareness Week, day by day Eight years after medical cannabis became legal to prescribe in the UK, we are taking the patient voice to race tracks, patient lounges, a public pop-up and No. 10 Downing Street. Pick a day, save the events you like, and add them to your calendar. –Days –Hours –Minutes –Seconds until MCAW 2026 begins on Sunday 1 November. See our planJoin our DiscordThe whole weekAdd your event PatientsCann UK® at MCAW 2026 Where we will be Our aim is to bring patients together, take accurate information into public spaces, help Drive Out Cannabis Stigma and show that prescribed patients belong everywhere. You do not need to come to the whole week. Some details are still being confirmed, so check back here. Help choose our pop-up On Thursday 5 November, the public picks where the PatientsCann UK® team holds an awareness pop-up. We will run the poll on Discord, Instagram and Facebook. Discord is the best place to vote, get updates through the week and meet other patients from anywhere in the UK. It is a safe, moderated space and free to join. Join our DiscordInstagramFacebook Want to help on the day? Our volunteers welcome patients, share resources and help capture the week. Become a volunteer and we will send you a full briefing. MCAW belongs to everyone The whole week at a glance Other groups are running their own events too. Here is what PatientsCann UK®, United Patients Alliance and MCUK have shared so far. Tap any event to see the details. Saved events are shaded, and anything that overlaps with another saved event is flagged. Running something yourself? Add your event. ShowPatientsCann UK®United Patients AllianceMCUK MCUK’s programme runs from Monday 2 to Sunday 8 November. Sunday 8 November falls outside the usual 1 to 7 November week. Other MCAW 2026 programmes What United Patients Alliance and MCUK are planning United Patients Alliance MCUK United Patients Alliance (UPA) is running a theme for each day of the week, starting with patient stories on 1 November. Session times have not all been shared yet. See the UPA MCAW page. MCUK is running evening sessions from Monday 2 to Sunday 8 November, with an extra afternoon session on Thursday 5 November. All times are UK time. MCUK says the speakers and panel line-ups are still being finalised, so there may be small changes to the session descriptions. Your event Running something for MCAW 2026? Add it to this page MCAW belongs to the whole community, and nobody needs permission to take part. If you are running an event or activity between 1 and 7 November, big or small, in person or online, tell us about it. We will check the details and add it to the week at a glance so more patients can find it. Your name Email Group or organisation (optional) Event name DayChoose a daySunday 1 NovemberMonday 2 NovemberTuesday 3 NovemberWednesday 4 NovemberThursday 5 NovemberFriday 6 NovemberSaturday 7 NovemberMore than one day Time (if known) How will people join? In personOnlineBoth Venue address, or online link What is happening? Website or social media link (optional) I agree to PatientsCann UK® storing these details so they can contact me about this event. I agree to the event name, day, time, place and description being shown on this page and shared on PatientsCann UK® social media. My name and email will not be published. Send my event Thank you. We have your event and will check the details before adding it to this page. Remember to share it with #MCAW and #MCAW2026. My week 0 My week Close Add all to my calendar

<p>The post MCAW 2026 first appeared on PatientsCann UK®.</p>

Interactive history The Cannabis History Atlas People have grown and used cannabis for thousands of years, for rope, food, medicine and faith. Drag the timeline to travel through time. The map shows each country’s cannabis laws in that year, and the pins show where key moments happened. Show 2026Today +–1:1 Key EarlierLater Read Play speed0.25x0.5x1x2x Pause at each moment ScrubbingNormalSlowFine Arrow keys jump between moments. Shift and arrow keys nudge the year. Legal status is simplified to one colour per country and dates before the 20th century are often approximate. Laws change often. If you travel with a prescription, check the current rules for the country you are visiting before you go. References

<p>The post Cannabis History Atlas first appeared on PatientsCann UK®.</p>

Medical Cannabis Awareness Week 2026: a week that belongs to everyone | PatientsCann UK® Skip to content Awareness1 to 7 November 2026Community owned Medical Cannabis Awareness Week belongs to everyone Every year, from 1 to 7 November, patients, carers, families and supporters across the UK speak up about medical cannabis. No one owns the week. It is run by the community, for the community, and anyone can take part. PatientsCann UK®Awareness#MCAW #MCAW2026 Get involved this November On this page What is MCAW? A week for everyone The logo Why a week Our tours This year Get involved References At a glance When1 to 7 NovemberThe first week of November, every year. Why then1 November 2018The day medical cannabis became legal to prescribe in the UK. Who owns itNo oneIt is community owned and community run. Everyone is welcome. Join in#MCAW2026Share your story, host an event, or simply talk about it. Where it began What is Medical Cannabis Awareness Week? Medical Cannabis Awareness Week, often shortened to MCAW, is a yearly week of events, stories and conversations about cannabis as a medicine. It starts on 1 November. That date matters. On 1 November 2018, medical cannabis became legal to prescribe in the UK.2 The week was first started in 2020 by PLEA (Patient-Led Engagement for Access), a patient advocacy group.1,4 Patients shared their stories, doctors and advocates joined online panels, and people across the UK were asked to talk about medical cannabis with friends and family.1 In 2023, the week marked five years since medical cannabis became legal to prescribe, and ran from 1 to 7 November as it does every year.4 By then, PLEA had closed. The week could have faded away. Instead, the community picked it up and carried it on. Patients, volunteers and small groups kept the week alive, and PatientsCann UK® stepped in to help it grow. Community owned A week that belongs to everyone No person, company or group owns Medical Cannabis Awareness Week. It belongs to every patient who has ever had to explain their medicine. PatientsCann UK® MCAW has always been bigger than any one organisation. It grew because patients wanted it and because people gave their time for free. When the group that started it closed, the week did not close with it. That tells you who it really belongs to. Nobody needs permission to take part. You do not need to sign up to anyone, pay a fee or use a set logo. A patient talking to their GP, a family sharing a story online, a clinic holding an open day, a local group meeting in a cafe: all of these are Medical Cannabis Awareness Week. We think it should stay that way. PatientsCann UK® takes part every year, and we will keep doing so, but the week is not ours. It is yours. What MCAW is Community owned and community run. Free for anyone to join, share and take part in. Led by patients, their carers and their families. A shared moment, every 1 to 7 November. What MCAW is not Not owned by any person, company or organisation. Not something anyone needs permission to take part in. Not a brand or a product to sell. Not closed to anyone who wants to help. Free for everyone The MCAW logo, and yours These are the logos PatientsCann UK® uses for Medical Cannabis Awareness Week. We first used our logo in 2024, together with United Patients Alliance and the Medical Cannabis Patients Alliance (MCPA), a patient group that has since closed. We added two more for 2025. All of our logos are in the public domain. There is no copyright on them. Anyone can download them, print them, share them or change them, with no need to ask. After PLEA closed, the original MCAW logo was shared by patients, groups and businesses across the community. That logo has since been claimed under copyright. We do not think any symbol of this week should belong to one organisation, so ours are free for all. 2024 logoPublic domain. Free for anyone to use.Download 2025 logo, lightPublic domain. Free for anyone to use.Download 2025 logo, darkPublic domain. Free for anyone to use.Download Make your own. We would love to see how you picture Medical Cannabis Awareness Week. Design your own MCAW logo, share it on social media, tag PatientsCann UK® and use the hashtags: #MCAW#MCAW2026 Keeping it focused Why a week works better than a month Last year, some in the industry suggested a Medical Cannabis Awareness Month. It did not get off the ground, and we did not support it. A longer campaign sounds bigger, but it would take away the impact of the week. One loud moment. When everyone speaks up in the same seven days, the message is heard. Spread across a month, the same voices get lost. It fits patients. Many patients live with pain, fatigue or long-term illness. A week is something people can manage. A month is a lot to ask. It keeps the anniversary at the centre. The week starts on 1 November, the day medical cannabis became legal to prescribe. That link is part of what makes it meaningful. It stays about patients. A short, focused week keeps the attention on real people and real stories. What we have done On the road every November since 2023 PatientsCann UK® first took Medical Cannabis Awareness Week on the road in 2023, with a trial tour of Brighton, Hove and Exeter. Since 2024, we have followed a set route from Northern Ireland to London. We travel the whole of the UK, so that patients in every nation have a chance to meet us, ask questions and feel less alone. In 2024, the tour took patient advocates to Belfast, Glasgow, Birmingham, Cardiff and London.3,5 Where we can, we also join other events along the way. 1Northern IrelandWe start the week in Northern Ireland. 2ScotlandThen across the water to Scotland. 3The middle of EnglandDown to the heart of England. 4WalesOut

<p>The post Medical Cannabis Awareness Week first appeared on PatientsCann UK®.</p>

PatientsCann UK | Some Are More Equal Than Others Skip to content Equality law Prescription discrimination Opinion and analysis Some Are More Equal Than Others… Medical cannabis patients are often told that they are protected by the Equality Act 2010. For many patients, that may be true. But it is not true simply because somebody has been prescribed cannabis. PatientsCann UK® Equality Act 2010 and medical cannabis By Sal Aziz, Director On this page A prescription is not a disability certificate Who decides Presumed disabled? Volunteers Capacity matters Routes to discrimination Exceptions Finding common ground References Please note This article is general information about equality law and how PatientsCann UK® approaches it. It is not legal or medical advice. The legal test A prescription is not a disability certificate The Equality Act protects disability as a legal status. It does not create a separate protected characteristic of being a patient, taking prescribed medication or holding a medical cannabis prescription. It also does not apply universally to every relationship between an individual and an organisation. Protection depends both on whether the person meets the statutory definition of disability and on the capacity in which the organisation is dealing with them. That distinction creates an uncomfortable question: if the same practical accommodation can safely be offered to every lawful patient, why should compassion depend on whether the patient can prove that their condition crosses a legal threshold? Section 6 of the Equality Act defines disability as a physical or mental impairment having a substantial and long-term adverse effect on a person’s ability to carry out normal day-to-day activities. “Substantial” means more than minor or trivial, while “long-term” generally means that the effect has lasted, or is likely to last, at least 12 months or for the rest of the person’s life. Recurring conditions can also qualify. Some conditions receive special treatment. Cancer, HIV infection and multiple sclerosis are disabilities from diagnosis. Progressive conditions may qualify before their effects become substantial where the statutory test is satisfied. The Act also protects people who previously had a qualifying disability, subject to limited exceptions. Crucially for medical cannabis patients, the assessment normally considers what the impairment would be like without the measures being used to treat or correct it. Schedule 1 expressly includes medical treatment within those measures. A patient whose condition is well controlled by cannabis is therefore not necessarily excluded from protection simply because the treatment works. The relevant question may be what the condition would probably do without that treatment. Many medical cannabis patients are prescribed for serious, persistent or recurring conditions and are therefore likely to satisfy the definition. It would, however, be unsafe to claim that every patient is legally disabled. A prescription may provide important evidence of an underlying impairment and treatment, but it does not by itself establish the substantial, long-term effect required by section 6. The Equality Act’s exclusion of addiction to alcohol, nicotine or another substance should not be confused with lawful treatment using a controlled drug. The 2010 Disability Regulations exclude addiction itself as an impairment, subject to an exception where it originally resulted from medically prescribed drugs or other medical treatment. In most medical cannabis cases, the asserted disability will in any event be the underlying physical or mental impairment, not an assumed addiction to the prescribed medicine. Japan has arguably the most formalised and structured official framework in the world. The government issues physical booklets called Shōgaishatechō (障害者手帳) or Disability Handbook. Applications are generally made through the relevant local authority and supported by medical or specialist evidence. The precise assessment process depends on the type of certificate and the municipality involved. Pictured above is a Seishin Shōgaisha Hoken Fukushi Techō (精神障害者保健福祉手帳) or Mental Disability Health and Welfare Handbook. Similar schemes exist in other countries, such as Germany’s Schwerbehindertenausweis for severe disabilities. Whilst The Sunflower Scheme is available for anyone who self-identifies as having a hidden disability, and PIP is available for those with qualifying disability or long-term condition, no directly comparable scheme exists in the UK. 精神 手帳 京都市.jpg by Bitland is licensed under CC BY 4.0 Evidence and burden Who decides whether somebody is disabled? There is no universal Equality Act disability card and no general process through which every patient obtains a binding declaration before requesting fair treatment. Outside litigation, organisations and individuals must make practical decisions using the information reasonably available to them. Evidence might include a patient’s account of functional effects, prescription records and, where proportionate, relevant clinical or occupational-health evidence. If a dispute reaches legal proceedings, the court or tribunal ultimately determines whether the statutory definition was satisfied at the relevant time. Section 136 provides a shifting burden of proof in discrimination proceedings once there are facts from which a court could conclude, in the absence of another explanation, that a contravention occurred. That procedural rule does not make a prescription conclusive proof of disability, but neither does it entitle organisations to dismiss credible evidence until a patient has obtained a judgment. This leaves patients in a difficult position. They may have to disclose intimate medical information to establish rights that an organisation could have respected voluntarily from the outset. The more evidence demanded, the greater the intrusion. Yet if too little information is provided, an organisation may argue that it did not know, and could not reasonably have been expected to know, of the disability, particularly in a claim for discrimination arising from disability. Policy, not finding Should patients be presumed disabled in practice? As a strict statement of law, organisations should not declare every medical cannabis patient disabled. Not every patient will meet the definition, and disability is a status belonging to the person, not a label produced by the medicine. But there is an important difference between making a legal finding and adopting an inclusive policy. An organisation can usually choose to extend a proportionate adjustment, such as secure medicine storage, a private administration area, flexible breaks or an individual risk assessment, without first

<p>The post Some are more equal than others first appeared on PatientsCann UK®.</p>

PatientsCann UK | The Endocannabinoid System Visualizer Skip to content Science Interactive Peer reviewed sources The endocannabinoid system, explained by exploring your own body Every person reading this has an endocannabinoid system. It is a network of tiny switches, messengers and clean-up crews that keeps the body steady. Tap any part of the body below to see which switches sit there and what they do. PatientsCann UK Education, physiology Written for patients, carers and clinicians On this page The basics Body map How the signal works Makers and breakers What it balances Plant compounds Entourage effect Beyond CB1 and CB2 For clinicians Test yourself References What this page is, and is not This page teaches the science of how the body works. It is not medical advice and it does not recommend any product, dose or treatment. If you think medical cannabis might help you, speak to your GP, your specialist or a clinic on the General Medical Council register. Why this matters It is already yours The system is built into every human body from the first weeks in the womb. Cannabis did not put it there. It keeps you steady Sleep, appetite, pain, mood, movement, temperature and the immune response all get nudged back towards the middle. It is very old Versions of this system appear in animals going back around 450 million years, which is why it is found in so many species. It explains the effects Cannabis compounds work because they fit switches your body already has. Different switches, different effects. Start here Three parts, one job: keeping you steady Your body is a colony of billions of cells. Each cell has its own needs, and they all have to work together. To do that, cells send each other chemical messages. The endocannabinoid system, often shortened to ECS, is one of those messaging networks. Scientists often describe it as a lock and key. The receptor is the lock, sitting on the outside wall of a cell. The messenger molecule is the key. When the right key turns the right lock, something changes inside that cell. The three parts The locks (receptors). Two main ones, called CB1 and CB2. They sit on cell surfaces all over the body and each one changes what its cell does. The keys (endocannabinoids). Fatty messenger molecules your body builds itself. The two main ones are anandamide and 2-AG. The clean-up crew (enzymes). Tools that build the keys when they are needed and destroy them seconds later. The main destroyers are called FAAH and MAGL. The part that surprises people Most messaging systems keep a stock of messengers ready in tiny bags, waiting to be released. The ECS does not. Endocannabinoids are made on demand, cut fresh out of the fatty wall of the cell at the exact moment they are needed, used on the spot, and then broken down. Nothing is stored and nothing travels far. That is why the ECS is so precise. It does not act on the whole body at once. It acts in one small place, for a short time, only where something needs correcting. The word for it is homeostasis. It means keeping the inside of your body steady even when things outside change. Not too hot, not too cold. Not too much pain signal, not too little. The ECS is one of the body’s main tools for doing that. Where the plant comes in The keys your body makes fit the locks perfectly. Compounds from the cannabis plant, called phytocannabinoids, are shaped closely enough to fit the same locks, but they are not identical. Researchers sometimes call them a false key. They turn the lock, but not in quite the same way, not in the same place, and not for the same length of time. That single idea explains almost everything else on this page. Cannabis does not create new effects in the body. It leans on a control system that is already running. It is not the cannabis plant that has many effects, it is the endocannabinoid system that determines them. Dr Mariano Garcia de Palau, Fundacion CANNA Interactive body map Where the receptors are, and what they do there Tap a numbered marker on the body, or a name in the row underneath. CB1 markers are green, CB2 markers are purple, and places with a real mix of both are teal. Show Everything CB1 only CB2 only 13 regions to explore CB1 CB2 Both, in real numbers A note on the drawing. The illustration shows the main organs from the front. Each marker sits over the area that region covers, so a few point at parts that sit deeper in the body. The immune marker sits on a cluster of lymph nodes, and nerves and skin reach everywhere, so those markers show one place out of many. Step by step How one nerve cell tells another to calm down Nerve cells talk across a tiny gap called a synapse. Normally messages travel one way. The ECS is unusual: its message travels backwards. Step through it below. Presynaptic sending neuron Postsynaptic receiving neuron the synaptic gap vesicles CB1 receptor on the sending cell receptors glutamate or GABA Ca2+ up DAGL 2-AG cut from the cell wall backwards fewer messages sent MAGL broken down in seconds Back Next step Why the backwards direction matters. The cell that is getting too much noise is the one that turns the volume down, at the exact synapse where the noise is coming from. Nothing else in the body is affected. This is called retrograde signalling, and it is the reason cannabinoids can quieten over-firing nerves without shutting the whole nervous system down. The cast The makers, the messengers and the breakers Six molecules do most of the work. Two carry the message, two build them, two destroy them. Tap any name. The others, in brief Anandamide and 2-AG get the attention, but the body makes more: Noladin ether and virodhamine, both weaker relatives. Virodhamine may work against

<p>The post Endocannabinoid System first appeared on PatientsCann UK®.</p>

Skip to the explorer PatientsCann UK · Patient education From Seed to Patient: the UK medical cannabis pipeline Every legal prescription in the UK travels the same route: a controlled growing room, a licensed factory, an accredited laboratory, a border, a specialist clinic and a pharmacy. This explorer walks you through all six stages, compares the seven formats a patient can be prescribed, and shows you how to read the paperwork that proves it. 6 regulated stages 7 patient formats Quality and science inspector This is education, not medical advice. Onset and duration figures are typical ranges reported for each route. Your own response depends on your dose, your product and your body. Never change how you take your medicine without speaking to your prescriber or pharmacist. See all patient resources 1 The seed to shelf journey 2 Formats and delivery pathways 3 Quality and science inspector The six stages of a legal UK prescription Select any stage to open the detail. Each one has its own quality standard and its own regulator, and a batch cannot move forward until the stage before it has been signed off. 1Genetics and GACP growing 2GMP processing and extraction 3Laboratory testing and CoA 4Licensed import and border 5Specialist prescribing 6Pharmacy dispensing Stage 1 of 6 1 Genetics, breeding and GACP cultivation Where the medicine starts: a known plant, grown the same way every time. Standard GACPRegulator DEFRA and origin inspectors What happens here A licensed grower keeps a small number of mother plants and takes cuttings from them, often through tissue culture, so that every crop is genetically the same plant rather than a new cross. Growing rooms are closed loop: light, temperature, humidity, carbon dioxide and air filtering are all controlled and logged. Mother plant care and cutting or tissue culture cloning Batch to batch genetic stability, checked crop by crop Sealed rooms with filtered air and monitored water feeds Quality standard GACP (Good Agricultural and Collection Practice). It sets how the plant is grown, fed, harvested and handled. In practice it means no synthetic pesticides, and soil, water and fertiliser chosen so the plant does not draw heavy metals up into the flower. Where the flower is dispensed as it is, GACP alone is not enough: the maker has to write down the point at which production of the active substance begins, and for whole flower that point is the growing room. Who regulates it DEFRA in the UK, alongside the agricultural inspectors of the country the crop is grown in. Growers are inspected and have to keep records for every batch they release. One decision sets the whole rulebook What the crop is going to become decides where pharmaceutical rules start. It is the single most important point in the chain, and the one most often got wrong. If the flower itself is the medicine The plant is the active substance Propagation Cultivation and flowering Harvest, drying, curing Packed flower, dispensed as it is Annex 2, biological medicines Nothing downstream can purify or sterilise a dried bud, so quality has to be built in from the cuttings onward. Annex 2 recognises that manufacture can begin at propagation. If the flower will be extracted The plant is a starting material Propagation Cultivation and flowering Harvest and drying Extraction and formulation Annex 7, herbal starting materials Here quality is defined later. Extraction, filtering and purification can take impurities out, so the plant is grown under GACP and pharmaceutical rules begin at the processing step. Why sameness matters A prescription only works as medicine if the next jar behaves like the last one. Controlled genetics and controlled rooms are what let a pharmacist put a fixed cannabinoid percentage on a label. Illicit supply has none of this: the same street name can be a different plant, grown a different way, with a different strength every time, and nobody has tested it. Next: GMP processing 2 Pharmaceutical processing and GMP extraction The crop becomes a pharmaceutical product in a cleanroom. Standard EU and UK GMPRegulator MHRA What happens here Harvested flower is dried and cured at a set temperature and humidity, then milled to a controlled particle size for vaporising. For oils and cartridges the plant material goes through supercritical carbon dioxide extraction, then winterisation to strip out fats and waxes, with any solvent recovered and accounted for. Controlled drying, curing and precision milling Cold carbon dioxide extraction under pressure Winterisation, filtration and solvent recovery Standardising the extract to a fixed cannabinoid strength Quality standard EU and UK GMP (Good Manufacturing Practice). Work happens in cleanrooms with ISO class 5 and class 7 air handling and positive air pressure, so air always flows out of the clean space rather than into it. Every step is written down, signed and traceable to the batch. The rulebook is EudraLex Volume 4: Part I for finished medicines, Part II for active substances, and Annex 2 for medicinal cannabis intended for use as whole flower. Quality risk management sits across all of it. Who regulates it The MHRA, the UK medicines regulator. A site that makes or releases a medicine for UK patients has to hold and keep its GMP certification through inspection. Three routes out of the same growing room Where GACP stops and GMP starts depends on what the batch is going to become. Requirements tighten at every step closer to the patient. GACP, pre harvestGMP, post harvestGood distribution practice Bulk flower for extractionMother plantsRooting and hardeningLarge scale cultivationharvestFast fan assisted dryingMachine trimmingBulk packaging and shippingExtractionActive ingredientFormulationFilling and packaging Sold on as feedstock, so the later GMP steps happen at another site. Extracts, including oils, hash and rosinMother plantsRooting and hardeningLarge scale cultivationharvestFast dryingMachine trimmingExtractionActive ingredientFormulationFilling and packagingDistribution Processing can remove impurities, so the finished extract is standardised before it is filled. Finished packaged flower (Flos)Mother plantsRooting and hardeningSmall scale cultivationharvestWet hang harvestSlow cool dryingHand trimmingCuringPackagingDistribution Covered end to end by GMP Annex 2. The flower itself is the finished medicine, so nothing can be cleaned out of it

<p>The post Seed To Patient first appeared on PatientsCann UK®.</p>

There is no excerpt because this is a protected post.

<p>The post Protected: Patient Experience – Colin Craig first appeared on PatientsCann UK®.</p>

There is no excerpt because this is a protected post.

<p>The post Protected: What Lucy McCarthy Told Us first appeared on PatientsCann UK®.</p>

There is no excerpt because this is a protected post.

<p>The post Protected: Why a motorsport team sponsored a motorsport team first appeared on PatientsCann UK®.</p>

Why a Medical Cannabis Not-for-Profit Started a Motorsports Team | PatientsCann UK® Skip to content Founder’s story Medical cannabis & motorsport Driving Out Cannabis Stigma Why a Medical Cannabis Not-for-Profit Started a Motorsports Team Before I knew medical cannabis was legal in the UK, motorsport was already my life. By Sal Aziz PatientsCann UK® Motorsports Team Founder’s story Team launch · Thruxton On this page Getting through the gate Becoming a patient When my case became policy Finding another route Why I have to race References One of my earliest racing memories is being told off for swearing after losing on Need for Speed: Underground. In my defence, I was only replicating my father! A few years later, he introduced me to Formula 1 after Lewis Hamilton joined the grid. I began watching properly in 2008 and was immediately hooked, waking at the crack of dawn when needed to see every race live. The highlight was Brazil 2008. My father walked out during the final lap, believing the championship was over, moments before Martin Brundle exclaimed: “Is that Glock?!” I had to scream for him to come back. I wanted to be part of that world, but racing appeared impossibly expensive. Even arrive-and-drive karting was beyond my budget. Then I discovered marshalling. Getting in Getting Through the Gate In 2021, I attended American SpeedFest at Brands Hatch. COVID restrictions meant unusually small crowds, giving the freedom to explore. Watching the marshals made me realise there was no reason I could not join them. I volunteered and was immediately hooked. Driving onto a circuit for the first time, even at 30 mph to reach my post, felt momentous. I was finally part of motorsport rather than watching from behind a screen or spectator fence. I went on to marshal events ranging from grassroots racing at Anglesey to the British Touring Car Championship and Goodwood Festival of Speed. I can even add “told Gordon Ramsay where to park at Goodwood” to my CV. Sal marshalling at Goodwood, as seen on Sky Sports F1. (Image source: Sky UK, used for illustrative purposes under Fair Dealing). “Told Gordon Ramsay where to park at Goodwood.” (Image source: Sky UK, used for illustrative purposes under Fair Dealing). I also competed in car trials, taking my Daewoo Lacetti off-road to see how far it could travel through marked sections. It was not Formula 1, but it was affordable, competitive and enormous fun. Author competing in a car trial (Image source: Woolbridge Motor Club, used for illustrative purposes under Fair Dealing). Treatment Becoming a Patient After a road trip through the Netherlands and an eventual drug-driving investigation in which I was found to be below the applicable limit, despite testing a wide range of cannabis products, I began exploring medical cannabis through the proper clinical route. My initial consultation took place on a Saturday morning at Silverstone before a day of marshalling. Once I began treatment, I noticed immediate improvements. Chief marshals commented positively on my performance. I completed the required health declarations and passed my flag assessment while openly prescribed medical cannabis. Author flag marshalling at the NASCAR Whelen Euro Series (Image source: GP1, used for illustrative purposes under Fair Dealing). Flag marshalling requires concentration, communication and rapid decisions in a safety-critical environment. I performed that role successfully and was excited to return to Goodwood for a second year, this time in the Supercar Paddock. Then a member of the public reported a marshal using cannabis. The report The Report That Began With a Smell I immediately acknowledged that the cannabis was mine and explained that it was legally prescribed for anxiety. I expected that explanation to resolve the concern. Instead, I was removed from post while senior Motorsport UK personnel were contacted. I was eventually permitted to continue in the lower-risk Supercar Paddock while the matter was reviewed. No performance failure or near miss had prompted the intervention. My medicine had become visible because of its smell. An odourless tablet may remain private. Cannabis flower can announce a patient’s treatment before they choose to discuss it. Smell is not evidence of impairment, but it can activate assumptions inherited from cannabis prohibition. That report eventually became much bigger than my individual case. Policy When My Case Became Policy In February 2024, Motorsport UK introduced Version 1 of a new signing-on declaration. It asked officials and marshals to confirm that they did not have disabilities or mental-health conditions, use drugs on the WADA Prohibited List, or take medication that might affect their duties. Motorsport UK later explained that the change followed reports during 2023 involving physical capability, mental health and the “substance use of colleagues”. I recognised myself in two parts of that explanation. Anxiety was my declared mental-health condition. Prescribed cannabis was my treatment, but it was apparently being framed as “substance use”. Although I was not named, the description reflected the defining features of my case. Version 1 of the officials declaration. Version 1 backfired horribly. Disabled volunteers and marshals taking medicines including blood thinners and asthma treatments began questioning whether they were still eligible. Medical cannabis was also independently identified as a problem. Within days, Motorsport UK issued Version 2, returning to a more sensible functional question: did the person’s condition or treatment adversely affect their duties? Version 2 of the officials declaration. But medical cannabis remained explicitly prohibited. My interpretation is that Version 1 attempted to capture cannabis through broad language about mental health, medication, “substance use” and the WADA list without initially announcing a cannabis-specific ban. When that language affected too many other volunteers, it was reversed, but cannabis patients remained excluded. I cannot prove the private intentions of those who wrote the policy. What I can say is that my case was followed by Version 1, the backlash, Version 2 and ultimately a categorical medical cannabis prohibition. Motorsport UK Public UK Licence Suspensions Register. Responsibility The Ban Is Not My Fault, but It Followed My Case I did not ban medical

<p>The post Why We Started a Motorsports Team first appeared on PatientsCann UK®.</p>

Race Report: Thruxton Retro, 4 July 2026 | PatientsCann UK® Skip to content Race report Thruxton Retro Team launch Race Report: Thruxton Retro, 4 July 2026 The PatientsCann UK® Motorsport Team successfully launched at Thruxton Retro on 4 July 2026, with founder Sal Aziz completing 15 drag-racing runs in his Vauxhall Insignia estate. By PatientsCann UK® Motorsports Team Race report Thruxton, 4 July 2026 15 runs completed On this page Preparing the car Arrival at Thruxton A green light Racing through the middle Fifteen runs Just the beginning References After securing a NORA Motorsport licence with his medical cannabis prescription declared, Sal immediately began looking for an opportunity to return to competitive motorsport. Thruxton was the natural choice. It was the circuit where Sal had first entered motorsport as a marshal, making it the perfect place to relaunch his motorsport career from behind the wheel. The build Preparing an Unlikely Race Car Preparation for the event was suitably grassroots. Sal crudely applied a cannabis-themed livery to his Vauxhall Insignia estate before we posted a teaser on social media. Despite the appearance, we were generating attention before the car had even reached the start line. The teaser: a cannabis-themed livery applied to the Vauxhall Insignia estate. Livery detail: a sports team for cannabis patients. The Insignia was not built for drag racing. It is a diesel estate, complete with a roof box, rather than one of the specially prepared machines normally associated with the drag strip. The team knew the Insignia was unlikely to be competitive against dedicated racing machinery. The first objective was simply to take part. A diesel estate with a roof box in the paddock, among purpose-built machinery. Race day Arrival at Thruxton Sal drove to Thruxton feeling the familiar mixture of excitement and nerves that accompanies any motorsport event. This time, however, those emotions were amplified by everything he had experienced in the sport. This was more than his first drag-racing event. It was his return to competitive motorsport as an openly prescribed medical cannabis patient. It was also the public launch of a team created to challenge the stigma and exclusion patients continue to experience. On arrival, event staff were understandably surprised to discover that the Vauxhall Insignia estate with a roof box was there to race. But one of the attractions of a Run What You Brung event is contained in the name: almost anything can be raced. Sal was directed to Thruxton’s runway, which had been transformed into a drag strip for the event. After signing on, the Insignia passed scrutineering and was cleared to take part. The unlikely race car was ready. Thruxton’s runway, transformed into a drag strip for the event. Launch A Green Light for the Team Sal drove into the staging area and joined the queue alongside a remarkable mixture of machinery. The entry included purpose-built drag cars, powerful performance vehicles, modified classics and ordinary road cars. As he moved towards the front of the queue and began staging at the lights, the significance of the moment finally sank in. To an observer, it may have looked like somebody preparing to drive an estate car quickly down a straight runway. To Sal and PatientsCann UK®, it represented something far greater. A medical cannabis patient who had been excluded from one pathway into motorsport had found another. He had declared his prescription, obtained a licence, passed scrutineering and reached the start line through the relevant processes. The lights changed. Sal accelerated down Thruxton’s runway. With that first green light, the PatientsCann UK® Motorsport Team was officially launched. Staging at the lights on Thruxton’s runway. The PatientsCann UK® Motorsports Team launch at Thruxton Retro. Symbolism Racing Through the Middle The location made the moment especially symbolic. Thruxton’s runway sits inside the main circuit. While Sal completed his runs under the NORA and Straightliners framework, Motorsport UK-regulated activity was taking place on the circuit around him. He was literally racing in the middle of the motorsport environment from which prescribed medical cannabis patients had been excluded under a different governing system. Same patient. Same prescription. Same condition. Different governance. PatientsCann UK® Motorsport Team The contrast demonstrated why PatientsCann UK® believes that transparent, evidence-based participation processes are possible. Safety remains essential, but automatic exclusion is not the only way in which a governing body can respond to legally prescribed medication. The results Fifteen Completed Runs 15 Completed runs 11.07s Best time 64mph Top terminal speed Once the first-run nerves had settled, Sal returned to the staging lanes repeatedly throughout the day. He raced against everything from specialist drag machinery to conventional road cars. Unsurprisingly, the diesel estate was not troubling the fastest competitors, but outright performance was never the primary objective. The official results record 15 completed runs. Sal’s best time was 11.07 seconds, with his runs generally finishing at between 61 and 64 mph. His highest recorded terminal speed was 64 mph. More importantly, Sal participated consistently throughout the event while managing and using his legally prescribed medication. One event cannot establish that every medical cannabis patient is suitable for every motorsport role. Patients, roles and circumstances differ. However, the day demonstrated that a prescribed patient could disclose their medication, follow a governing body’s process and participate repeatedly in a live motorsport environment. One of 15 completed runs down Thruxton’s runway. Perspective More Than a Result There were no trophies for the PatientsCann UK® Motorsport Team at Thruxton Retro, and the Insignia estate did not suddenly become a thoroughbred drag car. The achievement was reaching the start line at all. Each completed run made medical cannabis patients visible within motorsport for the right reasons: participating openly, following the rules and contributing to the event alongside everyone else. The day also showed what accessible motorsport can look like. Sal did not arrive with a purpose-built car, a professional crew or a huge racing budget. He arrived in his everyday Vauxhall estate with a homemade livery and a roof box. And he raced it.

<p>The post Race Report Thruxton Retro first appeared on PatientsCann UK®.</p>

Medical cannabis clinics refusing psychiatric patients | PatientsCann UK Skip to content News & Analysis Patient Rights Your Voice Counts Left in the dark: are private cannabis clinics turning their backs on psychiatric patients? Since a landmark coroner’s finding and the launch of Oliver’s Law, some private clinics appear to have swung from open doors to closed ones. We are hearing from patients who have been refused, discharged or flagged, often without a clear reason or a chance to reply. Here is what is happening, why it matters, and exactly what you can do. PatientsCann UK News & Advocacy Updated 10 August 2026 On this page What is happening Oliver’s story Our position Curaleaf responds Unmet need The cost Business reality A patient’s story What you can do SAR guide Share your experience References Please read gently This article touches on mental illness and, briefly, on the loss of a life. It is written with care, but please read at your own pace and step away if you need to. If you are struggling or in crisis, you are not alone: you can call the Samaritans free, day or night, on 116 123, or text SHOUT to 85258. This page is general information and support, not legal or medical advice. So you can read at your own pace, the most sensitive wording is hidden by default. Use the button to show it all, or tap any hidden word to reveal just that part. Show sensitive wording Why this matters A pattern, not one clinic Patients across several clinics report sudden refusals and discharges tied to mental health history. Safety and fairness Safe prescribing matters. So does the right to an individual assessment, accurate records and a fair review. You have rights You can see your records, correct mistakes and be heard. This page shows you how, step by step. The shift From open doors to closed ones For years, private medical cannabis clinics built their reputations on access and care. They advertised low barriers to entry and a compassionate approach to conditions the NHS often struggles to manage. For many patients, that promise was real, and life-changing. Recent months tell a more worrying story. Following greater regulatory pressure and a coroner’s report about prescribing safety, some clinics appear to have moved into a defensive crouch. Rather than working with patients to deliver safe, individual care, a number seem to be quietly closing the door on people with a mental health history, sometimes the very people who were welcomed a year or two ago. We want to be clear and fair. Some caution is understandable, and safe prescribing is not optional. But caution should mean better assessment, not blanket exclusion. When a clinic refuses or discharges someone without a proper look at their situation, and without a chance to reply, that is not safety. That is a patient being left in the dark. A pattern reported across the community This is not about a single clinic. Patients sharing their experiences on platforms such as Reddit and Facebook describe a wider trend, and while every case is different, the themes are strikingly consistent. These are patients’ own accounts, not statements from the clinics. Three concerns come up again and again: Screening at the door Some applicants say that declaring a mental health condition now brings a high chance of rejection, particularly for new patients. Misread records Others report being turned down over old or miscategorised GP notes, then having to file a Subject Access Request and wait weeks just to prove the notes were wrong. Lost continuity Some long-term patients say they have suddenly lost access to a settled prescription, leaving them without the continuity of care they relied on. Clinics patients have raised similar concerns about Curaleaf Medicann Mamedica Integro Patients have described experiences like these with the clinics listed above on public platforms such as Reddit and Facebook. These are patients’ own accounts rather than statements from the clinics, individual circumstances vary, and this list reflects what we have seen so far. We contacted each clinic named here and invited them to respond to the concerns raised in this article. None of them replied by the time we published, and we will gladly add or update their responses if they get in touch. In fairness, Curaleaf Clinic has separately issued a formal response in Oliver’s case, a public letter to the coroner rather than a reply to us, which we set out in what Curaleaf says. If your experience involves another clinic, please tell us using the form below. Share your experience If this has happened to you, please know it is not a reflection of your worth as a patient or a person. A refusal is a decision about a process, and processes can be questioned, corrected and appealed. The background Oliver’s story, and why clinics are reacting To understand the change, it helps to understand what came before it. Much of the current caution traces back to one deeply sad case, and to the campaign his family began in his memory. Oliver Robinson was 34. He lived with recurrent depression and a diagnosed dependency on cannabis. What happened to Oliver, and the inquest that followed, led to the first finding of its kind in the UK. We share the timeline below with care and respect for his family. Apr 2022 A prescription after one video call After a single video consultation, Oliver was prescribed high-strength medical cannabis for depression. Reports state the clinic relied on GP records printed around nine months earlier and did not contact his other treating psychiatrists first. Curaleaf disputes parts of this account and says the decision was approved by a multidisciplinary team; see what Curaleaf says. 2022-23 His health declined Over around 18 months his mental health grew more fragile. His healthcare professionals and family saw the cannabis as an obstacle to his recovery, and the prescription was seen to reinforce a dependency rather than easing it. Nov 2023 Losing Oliver On

<p>The post Psychiatric Patients Left in the Dark first appeared on PatientsCann UK®.</p>

3-Methyl-2-butene-1-thiol: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SVSC3 3-Methyl-2-butene-1-thiol prenylthiol, prenyl thiol, VSC3 pronounced: three-METH-il two-BYOO-teen one-THY-ol The number one skunk molecule. The main reason strong cannabis smells the way it does. Skunk & dieselFormula: C5H10SExtremely potent Aroma familySkunk FormulaC5H10S Mass102.20 g/mol Main noteSkunky 3-Methyl-2-butene-1-thiol · 102.20 g/mol The molecule Chemical structure This is the accurate skeletal structure of 3-Methyl-2-butene-1-thiol, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. SkunkyGassySulphurousPungent About What is 3-Methyl-2-butene-1-thiol? 3-Methyl-2-butene-1-thiol is the molecule most responsible for the strong, skunky smell people link with cannabis. It is often called prenylthiol. In 2021 a research team led by Iain Oswald pinpointed it as the number one skunk odorant in the plant. It carries a small chemical part called a prenyl group. This same building block turns up all over the cannabis plant, which may be why the smell feels so specific to cannabis. What the research says The Science Using a very sensitive method (two-dimensional gas chromatography with sulphur detection), the team measured this compound across many cultivars. The more of it a plant had, the more strongly people rated its skunky smell. It is powerful in tiny amounts. Even at a few parts per billion the nose picks it up easily, which is why a little goes a very long way. Aroma snapshot How 3-Methyl-2-butene-1-thiol Smells Skunk & diesel family SkunkyGassySulphurousPungent Smell strength: Extremely potent Detectable at just a few parts per billion. A tiny trace can fill a room. You might also smell it in: Skunk spray, and beer that has been left in the light (so-called “lightstruck” beer). Its role in the smell Part of the Whole On its own it smells purely skunky. Mixed with the fruity and piney terpenes, it helps give each cultivar its signature aroma. It sits alongside terpenes and cannabinoids as part of the plant’s full character. Good to know A Note on Safety 3-Methyl-2-butene-1-thiol is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions 3-Methyl-2-butene-1-thiol: Common Questions Is this what makes cannabis smell skunky? Yes. Research from 2021 found that 3-methyl-2-butene-1-thiol is the main molecule behind the classic skunky smell. The more a plant makes, the skunkier it tends to smell. Is it related to skunk spray or garlic? It belongs to the same broad family as the smelly molecules in skunk spray and garlic, called volatile sulphur compounds. That shared family is why all three can smell so strong. PreviousDimethyl trisulphide NextPrenyl thioacetate Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post prenylthiol first appeared on PatientsCann UK®.</p>

Prenyl thioacetate: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SPTA Prenyl thioacetate prenyl thioacetate, S-prenyl thioacetate pronounced: PREN-il thy-oh-ASS-uh-tate A close relative of the main skunk molecule, with a gassy, fuel-like twist. Skunk & dieselFormula: C7H12OSVery potent Aroma familySkunk FormulaC7H12OS Mass144.24 g/mol Main noteGassy S-(3-Methylbut-2-en-1-yl) ethanethioate · 144.24 g/mol The molecule Chemical structure This is the accurate skeletal structure of Prenyl thioacetate, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. GassySkunkySavourySulphurous About What is Prenyl thioacetate? Prenyl thioacetate is a close chemical cousin of the main skunk molecule. It carries the same prenyl building block, with a small acetate group added. It was described as part of the prenylated sulphur family found in cannabis. Its smell leans gassy and fuel-like. It is one of the compounds thought to sit behind the “diesel” or “gas” character that some cultivars are known for. What the research says The Science Like the other members of this family, it appears in very small amounts and needs sensitive sulphur-detecting equipment to measure. It tends to rise and fall alongside the main skunk molecule as the plant matures and is cured. Because it is so new to science, most of what is known is about its smell rather than any effect in the body. Aroma snapshot How Prenyl thioacetate Smells Skunk & diesel family GassySkunkySavourySulphurous Smell strength: Very potent Strong even in small amounts, with a gassy, fuel-like edge. You might also smell it in: The wider world of savoury, sulphur-rich smells shared with cooked garlic and onion. Its role in the smell Part of the Whole Adds a gassy, savoury layer on top of the pure skunk note. Blended with terpenes, it helps build the ‘gas’ profiles many people look for. Good to know A Note on Safety Prenyl thioacetate is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions Prenyl thioacetate: Common Questions What does ‘gassy’ or ‘diesel’ cannabis mean? Some cultivars smell a little like fuel or solvent. Sulphur compounds like prenyl thioacetate are part of where that gassy character comes from, working together with the plant’s terpenes. Is it the same as the main skunk molecule? No, but they are close relatives from the same family. This one has an extra acetate group, which nudges the smell towards gas and fuel. Previous3-Methyl-2-butene-1-thiol NextDiprenyl sulphide Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post prenyl-thioacetate first appeared on PatientsCann UK®.</p>

Prenyl methyl sulphide: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SPMS Prenyl methyl sulphide prenyl methyl sulphide, methyl prenyl sulphide pronounced: PREN-il METH-il SUL-fide A gentler prenyl sulphur compound with a savoury, umami feel. Garlic & savouryFormula: C6H12SModerately potent Aroma familyGarlic FormulaC6H12S Mass116.22 g/mol Main noteSavoury Methyl prenyl sulphide · 116.22 g/mol The molecule Chemical structure This is the accurate skeletal structure of Prenyl methyl sulphide, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. SavouryUmamiSulphurousMild garlic About What is Prenyl methyl sulphide? Prenyl methyl sulphide pairs the prenyl group with a small methyl group across a single sulphur atom. It is one of the softer members of the family. Rather than a sharp skunk or garlic hit, it adds a savoury, umami quality, a bit like the background depth in a slow-cooked stock. What the research says The Science Milder sulphur compounds like this one help round out a cultivar’s overall smell. They are easy to miss on their own but add richness to the whole. As with the rest of the family, the research so far is about aroma. Any effect in the body is unknown. Aroma snapshot How Prenyl methyl sulphide Smells Garlic & savoury family SavouryUmamiSulphurousMild garlic Smell strength: Moderately potent Softer than the others; savoury rather than sharp. You might also smell it in: Slow-cooked foods and broths, where gentle sulphur notes add background depth. Its role in the smell Part of the Whole Fills in the savoury middle of the aroma, giving body and depth beneath the brighter skunk and fruit notes. Good to know A Note on Safety Prenyl methyl sulphide is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions Prenyl methyl sulphide: Common Questions What does umami mean here? Umami is the savoury, moreish taste in foods like broth, mushrooms and parmesan. Prenyl methyl sulphide adds a smell with that same savoury depth. Is it as strong as the skunk molecule? No. It is one of the gentler compounds in the group, so it tends to sit in the background rather than take over. PreviousDiprenyl disulphide Next3-Mercaptohexan-1-ol Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Amagase, H. (2006) ‘Clarifying the real bioactive constituents of garlic’, Journal of Nutrition, 136(3), pp. 716S-725S. doi: 10.1093/jn/136.3.716S. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post prenyl-methyl-sulphide first appeared on PatientsCann UK®.</p>

Diprenyl sulphide: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SDPS Diprenyl sulphide di-prenyl sulphide, bis(3-methylbut-2-enyl) sulphide pronounced: dy-PREN-il SUL-fide Two prenyl groups joined by sulphur. Smells closer to garlic than to skunk. Garlic & savouryFormula: C10H18SVery potent Aroma familyGarlic FormulaC10H18S Mass170.31 g/mol Main noteGarlic Diprenyl sulphide · 170.31 g/mol The molecule Chemical structure This is the accurate skeletal structure of Diprenyl sulphide, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. GarlicAlliaceousSavouryOniony About What is Diprenyl sulphide? Diprenyl sulphide is built from two prenyl groups joined by a single sulphur atom. That shape is very close to the smell molecules garlic makes, which use two allyl groups instead of prenyl. Its smell is more garlic and onion than skunk. It is one of the compounds that first made scientists notice how much cannabis and garlic have in common. What the research says The Science Garlic’s sulphur compounds have been studied for years for possible heart and blood-vessel benefits. Because cannabis makes such similar molecules, researchers have raised the hopeful question of whether cannabis sulphur compounds might one day show benefits of their own. This is an early idea, not a proven fact. So far the science here is about smell and structure, not about treating any condition. Aroma snapshot How Diprenyl sulphide Smells Garlic & savoury family GarlicAlliaceousSavouryOniony Smell strength: Very potent Rich and savoury; carries clearly even at low levels. You might also smell it in: Garlic, onions, leeks and chives, which build their smells in a very similar way. Its role in the smell Part of the Whole Brings a savoury, garlicky layer to a cultivar’s aroma. It is one of the compounds that ties the smell of cannabis to the smell of the kitchen. Good to know A Note on Safety Diprenyl sulphide is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions Diprenyl sulphide: Common Questions Why does some cannabis smell like garlic? Compounds like diprenyl sulphide are built much like the smell molecules in garlic and onions. When a plant makes more of them, it can take on a savoury, garlicky edge. Does that mean cannabis has garlic’s health benefits? Not proven. The molecules look alike, which is why researchers are hopeful, but no study has yet shown that cannabis sulphur compounds share garlic’s effects. PreviousPrenyl thioacetate NextDiprenyl disulphide Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Amagase, H. (2006) ‘Clarifying the real bioactive constituents of garlic’, Journal of Nutrition, 136(3), pp. 716S-725S. doi: 10.1093/jn/136.3.716S. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post diprenyl-sulphide first appeared on PatientsCann UK®.</p>

Diprenyl disulphide: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SDPDS Diprenyl disulphide di-prenyl disulphide pronounced: dy-PREN-il dy-SUL-fide Like diprenyl sulphide, but with two sulphur atoms. Deep, garlicky and long-lasting. Garlic & savouryFormula: C10H18S2Very potent Aroma familyGarlic FormulaC10H18S2 Mass202.38 g/mol Main noteGarlic Diprenyl disulphide · 202.38 g/mol The molecule Chemical structure This is the accurate skeletal structure of Diprenyl disulphide, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. GarlicOnionySavouryAlliaceous About What is Diprenyl disulphide? Diprenyl disulphide is like diprenyl sulphide but with two sulphur atoms joined together in the middle. That extra sulphur makes the smell deeper and longer-lasting. It is a near mirror of diallyl disulphide, one of the most studied smell molecules in garlic. The main difference is the prenyl group in place of garlic’s allyl group. What the research says The Science Diallyl disulphide from garlic has been looked at for possible effects on blood pressure and blood vessels. The close match with diprenyl disulphide is what makes the cannabis-and-garlic comparison so striking. It is important to be clear: looking alike is not the same as acting alike. This stays a hopeful research direction, not a health claim. Aroma snapshot How Diprenyl disulphide Smells Garlic & savoury family GarlicOnionySavouryAlliaceous Smell strength: Very potent Deep and long-lasting; the double sulphur bond makes it cling. You might also smell it in: Cooked garlic and onion, which are rich in these two-sulphur “disulphide” smells. Its role in the smell Part of the Whole Adds a deep, clingy, savoury base note to the aroma. Two-sulphur compounds like this one tend to linger longer than lighter smells. Good to know A Note on Safety Diprenyl disulphide is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions Diprenyl disulphide: Common Questions What is the garlic molecule it copies? Diallyl disulphide. Garlic’s version uses an allyl group; the cannabis version uses a prenyl group. Otherwise they are built the same way, with two sulphur atoms in the middle. Is this why some cannabis smells strongly of garlic? Two-sulphur compounds like this one are deep and clingy. When a plant makes more of them, its savoury, garlicky side becomes easier to notice. PreviousDiprenyl sulphide NextPrenyl methyl sulphide Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Amagase, H. (2006) ‘Clarifying the real bioactive constituents of garlic’, Journal of Nutrition, 136(3), pp. 716S-725S. doi: 10.1093/jn/136.3.716S. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post diprenyl-disulphide first appeared on PatientsCann UK®.</p>

Dimethyl trisulphide: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SDMTS Dimethyl trisulphide dimethyl trisulphide, DMTS pronounced: dy-METH-il try-SUL-fide Three sulphur atoms in a row. A savoury, oniony smell found in cooked foods. Everyday sulphurFormula: C2H6S3Very potent Aroma familyEveryday FormulaC2H6S3 Mass126.31 g/mol Main noteSavoury Dimethyl trisulphide · 126.31 g/mol The molecule Chemical structure This is the accurate skeletal structure of Dimethyl trisulphide, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. SavouryOnionCookedMeaty About What is Dimethyl trisulphide? Dimethyl trisulphide, or DMTS, has three sulphur atoms joined in a row. That gives it a strong, savoury, oniony smell. It is common in cooked foods, from fried onions to aged cheese. In cannabis it adds a savoury, cooked depth to the overall aroma. What the research says The Science Like DMS, DMTS is found widely in food, so its smell is well known. It is far more powerful than DMS thanks to those extra sulphur atoms. In cannabis it is one of several savoury sulphur notes that sit beneath the brighter skunk and fruit smells. Aroma snapshot How Dimethyl trisulphide Smells Everyday sulphur family SavouryOnionCookedMeaty Smell strength: Very potent Powerful and savoury; a little reads as onion or cooked meat. You might also smell it in: Cooked onion, aged cheese, cooked cabbage and some cooked meats. Its role in the smell Part of the Whole Deepens the savoury base of the aroma, adding a cooked, oniony richness under the sharper top-notes. Good to know A Note on Safety Dimethyl trisulphide is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions Dimethyl trisulphide: Common Questions Why does some cannabis smell savoury or oniony? Compounds like dimethyl trisulphide, also found in cooked onions and cheese, add a savoury, cooked depth. They sit under the sharper skunk and fruity smells. Is DMTS stronger than DMS? Yes. The extra sulphur atoms make dimethyl trisulphide much more powerful, which is why even a little smells strongly savoury. PreviousDimethyl sulphide Next3-Methyl-2-butene-1-thiol Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post dimethyl-trisulphide first appeared on PatientsCann UK®.</p>

Dimethyl sulphide: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide SDMS Dimethyl sulphide dimethyl sulphide, DMS pronounced: dy-METH-il SUL-fide A simple, everyday sulphur smell found across many foods. Everyday sulphurFormula: C2H6SModerately potent Aroma familyEveryday FormulaC2H6S Mass62.13 g/mol Main noteSweetish Dimethyl sulphide · 62.13 g/mol The molecule Chemical structure This is the accurate skeletal structure of Dimethyl sulphide, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. SweetishCooked vegetableCabbageMarine About What is Dimethyl sulphide? Dimethyl sulphide, or DMS, is one of the simplest sulphur smells there is: two methyl groups either side of a single sulphur atom. It is everywhere in food and nature. You have smelled it in cooked sweetcorn and cabbage, in beer, and even in the sea air at the coast. In cannabis it adds a light, savoury background note. What the research says The Science Unlike the prenyl compounds, DMS is not special to cannabis. It turns up across the plant and food world, which is why it is so well understood. In cannabis it is a minor player, adding a soft savoury edge rather than a defining smell. Aroma snapshot How Dimethyl sulphide Smells Everyday sulphur family SweetishCooked vegetableCabbageMarine Smell strength: Moderately potent Familiar from cooking; sweetish at low levels, cabbagey when strong. You might also smell it in: Cooked sweetcorn, cabbage, the sea breeze, beer and truffles. Its role in the smell Part of the Whole Sits quietly in the background, adding a gentle savoury lift rather than a smell of its own. Good to know A Note on Safety Dimethyl sulphide is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions Dimethyl sulphide: Common Questions Is dimethyl sulphide unique to cannabis? No. It is one of the most common sulphur smells in nature, found in cooked vegetables, the sea and many drinks. In cannabis it plays only a small background role. Is it harmful? It is a normal, widespread food aroma present in trace amounts. It is the smell, not a medicine, and there is no known concern at these tiny levels. Previous3-Mercaptohexyl acetate NextDimethyl trisulphide Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post dimethyl-sulphide first appeared on PatientsCann UK®.</p>

3-Mercaptohexyl acetate: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide S3-MHA 3-Mercaptohexyl acetate 3-mercaptohexyl acetate, 3-sulfanylhexyl acetate, 3-MHA pronounced: three mer-KAP-toh-HEX-il ASS-uh-tate The passion-fruit molecule. The acetate cousin of 3-MH, even more tropical. Tropical & fruityFormula: C8H16O2SExtremely potent Aroma familyTropical FormulaC8H16O2S Mass176.28 g/mol Main notePassion fruit 3-Sulfanylhexyl acetate · 176.28 g/mol The molecule Chemical structure This is the accurate skeletal structure of 3-Mercaptohexyl acetate, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. Passion fruitTropicalFruityCitrus About What is 3-Mercaptohexyl acetate? 3-Mercaptohexyl acetate, or 3-MHA, is the acetate cousin of 3-MH. Adding the acetate group pushes the smell even further towards passion fruit and tropical punch. Like 3-MH, it is a star of flavour chemistry in wine and beer, and it was reported among the compounds behind fruity, exotic cannabis. What the research says The Science The 2023 study grouped 3-MHA with 3-MH as key drivers of tropical, fruity aromas in certain cultivars. The two often appear together. It is another extremely powerful smell, active at tiny concentrations. Aroma snapshot How 3-Mercaptohexyl acetate Smells Tropical & fruity family Passion fruitTropicalFruityCitrus Smell strength: Extremely potent An even punchier passion-fruit smell, powerful at trace levels. You might also smell it in: Passion fruit, tropical beers and white wines. Its role in the smell Part of the Whole Layers a ripe passion-fruit punch over the top of fruity cultivars, deepening their tropical character. Good to know A Note on Safety 3-Mercaptohexyl acetate is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions 3-Mercaptohexyl acetate: Common Questions What is the difference between 3-MH and 3-MHA? They are close cousins. 3-MHA has an extra acetate group, which shifts its smell from grapefruit towards passion fruit. They often occur together. Do these tropical smells mean the cannabis is stronger? No. Smell and strength are separate. A tropical aroma tells you about the plant’s sulphur compounds and terpenes, not about its cannabinoid content. Previous3-Mercaptohexan-1-ol NextDimethyl sulphide Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Oswald, I.W.H. et al. (2023) ‘Minor, nonterpenoid volatile compounds drive the aroma differences of exotic cannabis’, ACS Omega, 8(36), pp. 39203-39216. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post 3-mercaptohexyl-acetate first appeared on PatientsCann UK®.</p>

3-Mercaptohexan-1-ol: Aroma, Smell and Safety | PatientsCann UK Skip to main content Back to Sulphur Compounds Guide S3-MH 3-Mercaptohexan-1-ol 3-mercaptohexanol, 3-sulfanylhexan-1-ol, 3-MH pronounced: three mer-KAP-toh-HEX-an-ol The grapefruit molecule. A tropical, citrus thiol also famous in wine and beer. Tropical & fruityFormula: C6H14OSExtremely potent Aroma familyTropical FormulaC6H14OS Mass134.24 g/mol Main noteGrapefruit 3-Sulfanylhexan-1-ol · 134.24 g/mol The molecule Chemical structure This is the accurate skeletal structure of 3-Mercaptohexan-1-ol, drawn from PubChem data. Each corner and line-end is a carbon atom. The yellow S marks sulphur, the atom that gives this whole family its powerful smell. GrapefruitCitrusTropicalPassion fruit About What is 3-Mercaptohexan-1-ol? 3-Mercaptohexan-1-ol, or 3-MH, is a very different kind of sulphur compound. Instead of skunk or garlic, it smells of grapefruit, citrus and tropical fruit. It is well known outside cannabis. It is one of the molecules that give Sauvignon Blanc wine and certain hoppy beers their zesty, tropical lift. What the research says The Science A 2023 follow-up study reported that thiols like 3-MH help explain the fruity, tropical smell of some prized ‘exotic’ cannabis, a smell that terpenes alone could not account for. It is astonishingly powerful. The nose can detect it at parts per trillion, far below the level needed for most terpenes. Aroma snapshot How 3-Mercaptohexan-1-ol Smells Tropical & fruity family GrapefruitCitrusTropicalPassion fruit Smell strength: Extremely potent One of the most powerful smells known, detectable at parts per trillion. You might also smell it in: Sauvignon Blanc wine, tropical craft beers, grapefruit and passion fruit. Its role in the smell Part of the Whole Brings the bright, juicy, tropical top-notes to fruity cultivars, working hand in hand with citrus terpenes like limonene. Good to know A Note on Safety 3-Mercaptohexan-1-ol is an aroma compound, present in cannabis in trace amounts. It is not a medicine and has no dose of its own. What matters for you is the whole product and how it is prescribed. Always choose and adjust your medicine with your prescriber and pharmacist, never by smell alone. Questions 3-Mercaptohexan-1-ol: Common Questions Why does some cannabis smell of tropical fruit? Thiols such as 3-mercaptohexan-1-ol smell strongly of grapefruit and tropical fruit. A little goes a very long way, so even trace amounts can make a plant smell juicy and exotic. Is this the same molecule found in wine? Yes. 3-MH is one of the compounds that give Sauvignon Blanc wine and some tropical beers their grapefruit and passion fruit character. PreviousPrenyl methyl sulphide Next3-Mercaptohexyl acetate Back to full Sulphur Compounds Guide Important: This page is for education only. It is not medical advice. Research into cannabis sulphur compounds is very new, and most work so far is about smell, not treatment. The garlic comparison is about chemistry, not proven health effects. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Oswald, I.W.H., Ojeda, M.A., Pobanz, R.J., Koby, K.A., Buchanan, A.J., Del Rosso, J., Guzman, M.A. and Martin, T.J. (2021) ‘Identification of a new family of prenylated volatile sulfur compounds in cannabis revealed by comprehensive two-dimensional gas chromatography’, ACS Omega, 6(47), pp. 31667-31676. doi: 10.1021/acsomega.1c04196. Oswald, I.W.H. et al. (2023) ‘Minor, nonterpenoid volatile compounds drive the aroma differences of exotic cannabis’, ACS Omega, 8(36), pp. 39203-39216. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 3 August 2026).

<p>The post 3 Mercaptohexanol first appeared on PatientsCann UK®.</p>

Sulphur Compounds in Cannabis: The Skunk Molecule Explained | PatientsCann UK Skip to the compound library PatientsCann UK  ·  Education Understanding Sulphur Compounds Cannabinoids and terpenes get all the attention. But a third group of molecules, the volatile sulphur compounds, is the real reason cannabis can smell so skunky, so gassy, or so surprisingly tropical. Here is what they are, and why they matter to patients. 9 compounds The skunk molecule explained Live chemical structures The garlic connection On this page What they are Aroma families The garlic link Freshness & curing Why tests miss them The full family Questions References What are sulphur compounds? Sulphur compounds, or volatile sulphur compounds, are a group of smelly molecules the cannabis plant makes in tiny amounts. Volatile just means they float easily into the air, which is why you smell them the moment you open a jar. They were only pinned down recently. In 2021 a team of scientists found a whole new family of them in cannabis, and showed that one, called 3-methyl-2-butene-1-thiol, is the main reason strong cannabis smells skunky. What makes them special is their power. Where terpenes are measured in whole percentages, these sulphur compounds work at a few parts per billion. A trace is all it takes to change how a whole plant smells. The third pillar of aroma Think of cannabis smell as a three-legged stool. Cannabinoids like THC and CBD do the medical work. Terpenes bring the citrus, pine and floral notes. Sulphur compounds add the skunk, the gas and the tropical punch. Together they give every cultivar its signature. Explore the other two in our cannabinoids and terpenes guides. Interactive The Three Aroma Families Cannabis sulphur compounds fall into a few groups by how they smell: pungent skunk and diesel, savoury garlic, bright tropical fruit, and the milder everyday smells found in food. Pick any compound below to see its family, its smell, and how powerful it is. The hopeful part The Garlic Connection Here is the exciting bit. Many of the sulphur compounds in cannabis are built almost exactly like the ones in garlic. The only real difference is a small chemical part: cannabis uses a “prenyl” group where garlic uses an “allyl” group. Cannabis Prenyl thiol the skunk molecule nearly the same shape Garlic Allyl thiol a garlic molecule Why it matters: Garlic’s sulphur compounds have been studied for years for possible benefits to the heart and blood vessels. Because cannabis makes such close copies, scientists have raised a hopeful question: might the cannabis versions one day show benefits of their own? Hopeful research, not proven Interactive Freshness: Why Timing Changes the Smell Sulphur compounds are delicate. They build up late in the plant’s life, peak at just the right moment, then fade away. This is why the same flower can smell powerful one week and flat the next. Tap each stage to follow the journey. What this means for you: if aroma matters to you, fresher is usually better. Keep cannabis in an airtight container, somewhere cool and dark, and it will hold its smell for longer. Illustration based on greenhouse monitoring by Oswald and colleagues (2021). The exact rise and fall differ from plant to plant. Good to know Why Your Lab Report Misses Them If sulphur compounds matter so much to smell, why are they almost never listed on a product’s lab report? The answer is that they are genuinely hard to catch. 1 They hide in tiny amounts Sulphur compounds appear at parts per billion, or even parts per trillion. That is thousands of times less than a typical terpene, so they are very easy to walk straight past. 2 Normal tests are not tuned for them The usual lab equipment is set up to measure cannabinoids and terpenes. It is not designed to spot faint sulphur smells, so it often does not report them at all. 3 It takes special kit The 2021 discovery needed a powerful method called two-dimensional gas chromatography with sulphur detection. Very few routine labs run it. The takeaway: a lab report (sometimes called a COA) tells you about cannabinoids and often terpenes, but rarely these sulphur compounds. If they are missing from the paperwork, it does not mean they are missing from the jar. Often, your own nose is the better guide. Full library The Sulphur Compound Family Select any card to open the full profile, with its accurate chemical structure, how it smells, what the research says, and where else you meet it in daily life. Use the filters to narrow the list by aroma family. Filter: All Skunk & diesel Garlic Tropical Everyday Questions Sulphur Compounds: Your Questions Answered What makes cannabis smell skunky? The main reason is a volatile sulphur compound called 3-methyl-2-butene-1-thiol, sometimes called prenylthiol. In 2021 scientists showed that the more of it a plant makes, the skunkier it smells. It is powerful even at a few parts per billion, so a trace goes a long way. Are sulphur compounds the same as terpenes? No. Terpenes give the citrus, pine and floral notes and are measured in whole percentages. Sulphur compounds contain a sulphur atom, work at far lower amounts, and add the skunk, gas and tropical smells that terpenes alone cannot explain. You can read about the aroma side in our terpenes guide. Why do cannabis sulphur compounds get compared to garlic? Cannabis makes sulphur compounds built much like the ones in garlic and onion. Garlic’s versions have been studied for possible heart and blood-vessel benefits, which is why researchers are hopeful about the cannabis ones. It is important to be clear that this is an early idea, not a proven health benefit. Does fresh cannabis smell stronger? Usually yes. Sulphur compounds rise in the last weeks of flowering and peak during curing, then fade once a jar is opened and over months of storage. Storing your cannabis airtight, cool and dark helps keep the aroma for longer. Why are sulphur compounds not on my

<p>The post Sulphur Compounds first appeared on PatientsCann UK®.</p>

Open Letter on Patient Access, Welfare and Moderation Transparency | PatientsCann UK® Skip to content Open letter Patient welfare Public statement Open letter: why free patient help is being blocked on r/ukmedicalcannabis PatientsCann UK CIC is a non-profit. Our help is free, and it always will be. Yet for around four years we have watched our free patient resources be filtered, removed and then banned on the r/ukmedicalcannabis subreddit. This is our open letter. It sets out what happened, the reasons we were given, our honest answer to each one, and where you can always find us. PatientsCann UK CIC Open letter 30 July 2026 Read our free resources On this page The core issue Timeline Our directors Reasons and our answer Why it harms patients Our commitment Find us References About this letter This is an open statement of our own experience, shared to inform patients and to invite fair dialogue. It is not legal advice. In the screenshots below, moderator names have been removed, and the only accounts shown are our own team’s. The screenshots also show our former name and website, The Sanskara Platform; we now operate as PatientsCann UK CIC. Who we are PatientsCann UK CIC is a registered Community Interest Company. A CIC is a non-profit set up to serve the community, not to make money for owners. We exist to give UK medical cannabis patients free, honest information, legal guidance and support. We take no payment from patients for any of it. We are writing this letter because free, non-profit patient resources, ours and those we are linked to, keep being filtered, removed and banned on one of the busiest patient forums in the country: the r/ukmedicalcannabis subreddit. We have asked, appealed, and offered to follow every rule. Time and again we have been met with silence. Why this matters Free, not for profit Every guide, legal framework and toolkit we make is free. We take no money from patients, ever. Removed and banned Our links and crossposts were filtered, our posts held for approval, and then we were permanently banned. Appeals ignored Our requests, formal appeals and offers to talk have gone unanswered for years. The core issue Gatekeeping essential patient information UK medical cannabis is new, complex, and changing fast. Patients lean on each other, and on trusted independent guidance, to stay safe and to stay legal. When the first forum a worried patient finds removes free, non-commercial education, patients are the ones who lose out. Over the past few years we have found that resources produced by, or linked to, PatientsCann UK have been filtered and removed from r/ukmedicalcannabis. This has even included content where we were not the only author, but were simply named as a contributor or a source. At the time we operated under our former name, The Sanskara Platform, and links to that free resource site, along with crossposts linked to our work, were blocked. The pattern we have seen: free help is treated as advertising, links are quietly filtered, appeals are ignored, and the door is closed with no clear right to reply. What we have experienced A documented timeline Around 4 years agoOur links removed, our crossposts blocked Links to our free resource site were being automatically removed, and crossposts from our patient committee subreddit were disabled. When we asked why, the moderators told us the material was being treated as advertising, because our website “appears to be built by and partnered with companies and consultancies in the medical cannabis sector.” Our answer at the time was simple: the site exists to give patients resources and education, and it makes no money from those links. Moderation reply confirming our links and crossposts were being automatically filtered as “advertising”, and our response explaining the resources are free. Around 4 years agoA patient resource taken down A post explaining how to verify a patient was removed under the “no advertising” rule. In the same message, the moderator accepted that the post “does contain a patient resource”, but removed it anyway. A free patient resource removed under the “no advertising” rule, even though the moderator accepted it was a genuine patient resource. Around 4 years agoPosting rights limited to approval only After a month-long ban was lifted, we were told we were not banned. In practice, every post and comment we made would be held back and would only appear if a moderator approved it first. Told we were “not banned”, but that every post and comment would have to wait for a moderator to approve it. Around 3 years agoWe tried again, in good faith We reached out again, calmly, hoping to reach “a mature conclusion” about the block on our resources. We explained that patients ask the same questions every day, questions our free guides already answer, and asked to talk it through so we could move forward together. Our good-faith request to reopen the conversation and find a fair way forward for the community. Around 3 years agoA permanent ban, and a question turned back on us We were then permanently banned from taking part in r/ukmedicalcannabis. When we asked for a clear reason, and suggested an independent review of the decision, the reply did not answer the point. Instead it turned the question back on us, saying that if anything needed investigating, it was our “backing and investors.” The permanent ban notice, and the exchange that followed when we asked for reasons and an independent review. This year, MarchA fresh request for review, met with silence Most recently, in March, we sent a calm, respectful request to revisit the ban. We explained that we were never given a clear or definitive reason, and that we simply wanted the chance to put it right. As with our earlier appeals, we received no meaningful reply. Our most recent request for review, sent in good faith and, once again, left unanswered. Not one account This reached others. The messages above are from our Managing Director. But

<p>The post Open Letter Reddit first appeared on PatientsCann UK®.</p>

THCA: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide THCA THCA THCA, THC-acid, 2-COOH-THC pronounced: tet-ruh-hy-droh-kuh-nab-ih-NOL-ik AS-id The raw, unheated form of THC. Not intoxicating until it is heated. Acidic (raw) cannabinoidFormula: C22H30O4Intoxicating: No TypeAcidic (raw) FormulaC22H30O4 IntoxicatingNo Key focusInflammation Tetrahydrocannabinolic acid · 358.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of THCA, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C22H30O4 and it weighs 358.5 g/mol. Anti-inflammatoryAnti-sicknessNeuroprotectiveRaw / unheated About What is THCA? Tetrahydrocannabinolic acid, or THCA, is the raw form of THC found in fresh, living and undried cannabis. Here is the surprising part: THCA is not intoxicating. Eating raw cannabis flower will not get you high. THCA carries an extra acid group that THC does not have. That group is the reason the two behave so differently. In the body How THCA Works The acid group on THCA stops it from fitting the CB1 receptor well, so it does not cause a high. Instead, research suggests THCA acts on other targets, including PPAR-gamma receptors, and shows anti-inflammatory activity a little like some common painkillers. Early studies, mostly in the lab and in animals, have looked at THCA for inflammation, nausea, and protecting nerve cells. Some patients use raw cannabis, for example in juices, to get THCA without the high. Receptor snapshot Where THCA Acts The endocannabinoid system has two main receptors. Here is how strongly THCA acts on each. CB1Brain & nervous systemNone Its bulky acid group stops it fitting CB1 well. This is why raw, unheated cannabis does not make you high. CB2Immune system & bodyWeak / indirect Weak action at CB2. Beyond CB1 and CB2: Acts on PPAR-gamma and has COX / anti-inflammatory activity. In the plant How THCA is Made THCA is made from the mother acid CBGA by an enzyme called THCA synthase. It is the main cannabinoid in most dried high-THC flower, before it is heated. When you vape, smoke or cook the flower, heat removes a carbon dioxide group and turns THCA into THC. This is the single most important step in making cannabis intoxicating. PathwayTHCAadd heat →Delta-9-THC Good to know Safety and Side Effects THCA in its raw form is not intoxicating and appears well tolerated. The main practical point is that heat, even gentle warmth over time, converts it into intoxicating THC, so a “raw” product can change if it is warmed or stored badly. Human safety data is limited. Speak to your prescriber before using raw or high-THCA products. Questions THCA: Common Questions Why does raw cannabis not get you high? Because fresh cannabis contains THCA, not THC. THCA carries an extra acid group that stops it fitting the CB1 receptor. Only when you heat it (smoking, vaping or cooking) does it lose that group and become intoxicating THC. Is THCA the same as THC? No, but they are closely related. THCA is the raw, acidic form. Heat removes a carbon dioxide molecule and turns THCA into THC – a process called decarboxylation. PreviousCBDV NextCBDA Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nadal, X. et al. (2017) ‘Tetrahydrocannabinolic acid is a potent PPAR-gamma agonist with neuroprotective activity’, British Journal of Pharmacology, 174(23), pp. 4263-4276. doi: 10.1111/bph.14019. Moreno-Sanz, G. (2016) ‘Can you pass the acid test? Critical review and novel therapeutic perspectives of delta-9-tetrahydrocannabinolic acid A’, Cannabis and Cannabinoid Research, 1(1), pp. 124-130. doi: 10.1089/can.2016.0008. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post THCA first appeared on PatientsCann UK®.</p>

THCV: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide THCV THCV THCV, tetrahydrocannabivarin pronounced: tet-ruh-hy-droh-kuh-NAB-ih-vair-in THC’s slimmer cousin – it can dial the CB1 receptor down or up depending on the dose. Neutral cannabinoidFormula: C19H26O2Intoxicating: Dose-based TypeNeutral FormulaC19H26O2 IntoxicatingDose-based Key focusAppetite Tetrahydrocannabivarin · 286.4 g/mol The molecule Chemical structure This is the accurate skeletal structure of THCV, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C19H26O2 and it weighs 286.4 g/mol. Appetite controlFocusBlood-sugarEnergy About What is THCV? Tetrahydrocannabivarin, or THCV, is a slimmer cousin of THC. It has a shorter carbon “tail”, three carbons instead of five, and that small change gives it some surprising behaviour. THCV is found in higher amounts in certain plants, particularly some varieties from Africa and Asia. At the low doses usually found in products, it is not intoxicating. In the body How THCV Works THCV is unusual because its effect flips with dose. At low doses it blocks the CB1 receptor, the opposite of what THC does, which is why it is being studied to curb appetite. At high doses it can switch CB1 on instead, more like THC. It also acts as a partial activator of CB2. This double action has made THCV interesting for weight management, and for blood-sugar control in type 2 diabetes, where early trials look promising but are still small. Receptor snapshot Where THCV Acts The endocannabinoid system has two main receptors. Here is how strongly THCV acts on each. CB1Brain & nervous systemDampens / blocks At low doses it BLOCKS CB1 – the opposite of THC – which may curb appetite. At high doses it can switch CB1 on instead. CB2Immune system & bodyPartial Acts as a partial activator of CB2. In the plant How THCV is Made THCV comes from its acid, THCVA, which sits on a separate “propyl” branch of the family tree. This branch starts from CBGVA, the shorter-tailed version of the mother acid CBGA. As with the others, heat turns THCVA into THCV. Comes fromTHCVA→ add heat →THCV Good to know Safety and Side Effects THCV appears well tolerated in early studies, with few side effects at the doses tested. Because it can behave like THC at high doses, very strong products could in theory be intoxicating. Research in people is still limited, so speak to your prescriber before using THCV, especially if you manage diabetes or take medicines that affect appetite or blood sugar. Questions THCV: Common Questions Is THCV an appetite suppressant? At low doses THCV blocks the CB1 receptor, the opposite of THC, which is why it is being studied for appetite control and weight management. At high doses this can flip and it may activate CB1 instead. What makes THCV different from THC? THCV has a shorter carbon “tail” (three carbons instead of five). This small change flips how it behaves at the CB1 receptor at low doses. PreviousCBC NextCBDV Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Pertwee, R.G. (2008) ‘The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-9-tetrahydrocannabivarin’, British Journal of Pharmacology, 153(2), pp. 199-215. doi: 10.1038/sj.bjp.0707442. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006. Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post THCV first appeared on PatientsCann UK®.</p>

Delta-8-THC: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide 8-THC Delta-8-THC delta-8-THC, delta eight pronounced: DEL-tuh ate tet-ruh-hy-droh-kuh-NAB-ih-nol A close cousin of THC with the double bond in a different place – usually milder. Neutral cannabinoidFormula: C21H30O2Intoxicating: Yes TypeNeutral FormulaC21H30O2 IntoxicatingYes Key focusMilder high Delta-8-tetrahydrocannabinol · 314.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of Delta-8-THC, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C21H30O2 and it weighs 314.5 g/mol. Milder highAnti-sicknessPain reliefAppetite About What is Delta-8-THC? Delta-8-THC is a close relative of ordinary delta-9-THC. The two molecules are almost identical; the only difference is where one double bond sits in the ring. That tiny change is enough to make delta-8 behave a little differently. It occurs naturally in cannabis only in very small amounts. Most delta-8 sold abroad is made in a lab from CBD, which is a very different thing from a plant extract. In the body How 8-THC Works Delta-8 switches on the same CB1 receptor as delta-9-THC, so it is intoxicating, but it holds on a little less tightly. Many people describe its effects as milder and clearer-headed, with less anxiety, though this varies from person to person. It is also more chemically stable than delta-9-THC, meaning it breaks down more slowly. Research on delta-8 in people is limited compared with delta-9-THC. Receptor snapshot Where 8-THC Acts The endocannabinoid system has two main receptors. Here is how strongly Delta-8-THC acts on each. CB1Brain & nervous systemPartial Switches on CB1 like Delta-9-THC, but holds on a little less tightly, so the effects are usually milder. CB2Immune system & bodyPartial Also binds CB2. In the plant How 8-THC is Made In the plant, only a trace of delta-8 forms, partly as delta-9-THC slowly degrades. Because there is so little of it naturally, commercial delta-8 is usually made in a lab by converting CBD. This is why product quality and purity matter so much. Comes fromDelta-9-THC→ add heat →Delta-8-THC Good to know Safety and Side Effects Delta-8 can cause the same kinds of effects as THC, including a fast heartbeat, dry mouth and drowsiness, and it affects driving. A bigger concern is quality: lab-made delta-8 products, especially unregulated ones, can contain leftover chemicals and unknown by-products. In the UK, delta-8-THC is a controlled substance, the same as delta-9-THC. Only use cannabinoids from a regulated, prescribed source. Questions Delta-8-THC: Common Questions Is delta-8-THC the same as normal THC? Almost. Delta-8 and delta-9-THC differ only by where one double bond sits in the ring. That small change makes delta-8 bind the CB1 receptor a little less tightly, so its effects are usually milder. Is delta-8-THC legal in the UK? Delta-8-THC is a controlled substance in the UK, the same as delta-9-THC. Much of what is sold abroad as “delta-8” is made in a lab, not from the plant. PreviousCBN NextCBC Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Kruger, D.J. and Kruger, J.S. (2022) ‘Consumer experiences with delta-8-THC: medical use, pharmaceutical substitution, and comparisons with delta-9-THC’, Cannabis and Cannabinoid Research, 7(6), pp. 866-876. doi: 10.1089/can.2021.0124. ElSohly, M.A. and Gul, W. (2014) ‘Constituents of Cannabis sativa’, in Pertwee, R. (ed.) Handbook of Cannabis. Oxford: Oxford University Press, pp. 3-22. Pertwee, R.G. (2008) ‘The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-9-tetrahydrocannabivarin’, British Journal of Pharmacology, 153(2), pp. 199-215. doi: 10.1038/sj.bjp.0707442. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post Delta-8-THC first appeared on PatientsCann UK®.</p>

CBGA: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide CBGA CBGA CBGA, “the mother acid” pronounced: kan-uh-bih-jer-OL-ik AS-id The true “mother” – the acid the plant turns into every other cannabinoid. Acidic (raw) cannabinoidFormula: C22H32O4Intoxicating: No TypeAcidic (raw) FormulaC22H32O4 IntoxicatingNo Key focusPrecursor Cannabigerolic acid · 360.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of CBGA, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C22H32O4 and it weighs 360.5 g/mol. PrecursorMetabolicAnti-inflammatoryRaw / unheated About What is CBGA? Cannabigerolic acid, or CBGA, is where the whole cannabinoid story begins. It is the very first cannabinoid the cannabis plant makes, and it is often called the “mother cannabinoid” because everything else is built from it. On its own, CBGA is not intoxicating. It is a raw acid, and most of it is quickly turned into other cannabinoid acids as the plant grows. In the body How CBGA Works CBGA does not act strongly on the CB1 or CB2 receptors directly. Its main role is as a building block. Inside the plant, three different enzymes take CBGA and turn it into THCA, CBDA or CBCA, which then become THC, CBD and CBC when heated. Because it is a starting material rather than a finished product, CBGA has been studied less as a medicine, though early research is beginning to look at it for metabolism and inflammation. Receptor snapshot Where CBGA Acts The endocannabinoid system has two main receptors. Here is how strongly CBGA acts on each. CB1Brain & nervous systemNone Does not act on CB1 directly. CB2Immune system & bodyNone Does not act on CB2 directly. Beyond CB1 and CB2: The starting molecule. The plant’s enzymes turn CBGA into THCA, CBDA and CBCA. Early research looks at PPAR receptors and metabolism. In the plant How CBGA is Made CBGA is built when the plant joins a molecule called olivetolic acid with a terpene building block, geranyl pyrophosphate, using an enzyme called CBGA synthase. From there, CBGA is the crossroads of the whole family. If it is simply heated, it becomes CBG. If the plant’s enzymes act on it first, it becomes the acids that lead to THC, CBD and CBC. PathwayCBGAadd heat →CBG Good to know Safety and Side Effects There is very little human safety data on CBGA, because it is usually converted into other cannabinoids rather than used on its own. It is not intoxicating. Treat any CBGA product as experimental and speak to your prescriber before trying it. Questions CBGA: Common Questions What is CBGA? CBGA (cannabigerolic acid) is the first cannabinoid the cannabis plant makes. It is often called the “mother cannabinoid” because the plant’s enzymes turn it into the acids that become THC, CBD and CBC. Does CBGA turn into CBG? Yes. When CBGA is heated it loses its acid group (a process called decarboxylation) and becomes CBG. PreviousCBDA NextDelta-9-THC Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nachnani, R., Raup-Konsavage, W.M. and Vrana, K.E. (2021) ‘The pharmacological case for cannabigerol’, Journal of Pharmacology and Experimental Therapeutics, 376(2), pp. 204-212. doi: 10.1124/jpet.120.000340. Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026). Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006.

<p>The post CBGA first appeared on PatientsCann UK®.</p>

CBDV: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide CBDV CBDV CBDV, cannabidivarin pronounced: kan-uh-bih-dih-VAIR-in CBD’s slimmer cousin – non-intoxicating and studied for seizures. Neutral cannabinoidFormula: C19H26O2Intoxicating: No TypeNeutral FormulaC19H26O2 IntoxicatingNo Key focusSeizures Cannabidivarin · 286.4 g/mol The molecule Chemical structure This is the accurate skeletal structure of CBDV, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C19H26O2 and it weighs 286.4 g/mol. Anti-seizureCalmingAnti-sicknessAnti-inflammatory About What is CBDV? Cannabidivarin, or CBDV, is the slimmer cousin of CBD, with a shorter carbon tail. Like CBD, it does not make you high. It is usually a minor part of the plant, though some varieties, especially certain landrace plants from Asia, contain more of it. In the body How CBDV Works CBDV has very little direct action at the CB1 and CB2 receptors. Instead it works mainly through the body’s TRP channels, which are involved in pain, inflammation and the control of nerve excitability. Its most studied use is as an anticonvulsant. Animal research has shown it can reduce seizures, and it has also been explored for behaviours linked with autism. Human research is still at an early stage. Receptor snapshot Where CBDV Acts The endocannabinoid system has two main receptors. Here is how strongly CBDV acts on each. CB1Brain & nervous systemNone Very little direct action at CB1, so no high. CB2Immune system & bodyWeak / indirect Weak action at CB2. Beyond CB1 and CB2: Acts on TRP channels. Being studied for epilepsy and for behaviours linked with autism. In the plant How CBDV is Made CBDV is made from its acid, CBDVA, on the same “propyl” branch of the family tree as THCV, starting from the shorter-tailed mother acid CBGVA. Heat turns CBDVA into CBDV. Comes fromCBDVA→ add heat →CBDV Good to know Safety and Side Effects CBDV has been well tolerated in the clinical trials done so far, with mild side effects such as stomach upset. As an experimental compound, its long-term safety is still being studied. It is not a licensed medicine on its own, so only use it under the guidance of a prescriber. Questions CBDV: Common Questions What is CBDV used for? CBDV is being researched mainly as an anticonvulsant, for epilepsy, and for behaviours associated with autism. It is still experimental and not a licensed medicine on its own. Does CBDV get you high? No. Like CBD, CBDV is non-intoxicating and does not activate the CB1 receptor. PreviousTHCV NextTHCA Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Hill, A.J. et al. (2012) ‘Cannabidivarin is anticonvulsant in mouse and rat’, British Journal of Pharmacology, 167(8), pp. 1629-1642. doi: 10.1111/j.1476-5381.2012.02207.x. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026). Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4.

<p>The post CBDV first appeared on PatientsCann UK®.</p>

CBDA: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide CBDA CBDA CBDA, CBD-acid pronounced: kan-uh-bih-dy-OL-ik AS-id The raw, unheated form of CBD. Studied for nausea and inflammation. Acidic (raw) cannabinoidFormula: C22H30O4Intoxicating: No TypeAcidic (raw) FormulaC22H30O4 IntoxicatingNo Key focusNausea Cannabidiolic acid · 358.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of CBDA, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C22H30O4 and it weighs 358.5 g/mol. Anti-sicknessAnti-inflammatoryCalmingRaw / unheated About What is CBDA? Cannabidiolic acid, or CBDA, is the raw form of CBD found in the fresh plant. Like CBD, it does not make you high. It was one of the first cannabinoids ever isolated, back in the 1950s. CBDA carries an extra acid group compared with CBD, which changes how it behaves in the body. In the body How CBDA Works CBDA has a couple of interesting actions. It blocks an enzyme called COX-2, which is the same target as some anti-inflammatory painkillers, and it strongly activates the serotonin 5-HT1A receptor, which is closely involved in feeling sick. Because of this, the strongest early research on CBDA is for nausea and vomiting, where animal studies suggest it may be even more powerful than CBD itself. It is also being explored for inflammation and anxiety. Receptor snapshot Where CBDA Acts The endocannabinoid system has two main receptors. Here is how strongly CBDA acts on each. CB1Brain & nervous systemNone Does not fit CB1, so no high. CB2Immune system & bodyNone Little action at CB2. Beyond CB1 and CB2: Blocks COX-2 (like some anti-inflammatory medicines) and acts strongly on 5-HT1A serotonin receptors, which are linked to nausea. In the plant How CBDA is Made CBDA is made from the mother acid CBGA by an enzyme called CBDA synthase. It is the main cannabinoid in fresh CBD-rich plants before heating. Heat removes a carbon dioxide group and turns CBDA into CBD. This happens slowly even at room temperature, which is why fresh plants are richer in the acid. PathwayCBDAadd heat →CBD Good to know Safety and Side Effects CBDA appears well tolerated in the limited research available. As it is not intoxicating, it does not carry the “high”-related risks of THC. Its long-term safety in people is not yet well established. CBDA is less stable than CBD and slowly turns into it with heat and time. Tell your prescriber before using a raw or high-CBDA product. Questions CBDA: Common Questions What is CBDA good for? Early research suggests CBDA may help with nausea and inflammation, partly by acting on serotonin (5-HT1A) receptors. It is still experimental and not a licensed medicine. How is CBDA different from CBD? CBDA is the raw, acidic form found in the living plant. Heat removes its acid group and turns it into CBD, the form most people are familiar with. PreviousTHCA NextCBGA Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Bolognini, D. et al. (2013) ‘Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation’, British Journal of Pharmacology, 168(6), pp. 1456-1470. doi: 10.1111/bph.12043. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026). Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4.

<p>The post CBDA first appeared on PatientsCann UK®.</p>

CBC: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide CBC CBC cannabichromene pronounced: kan-uh-bih-KROH-meen A quiet, non-intoxicating cannabinoid studied for pain and mood. Neutral cannabinoidFormula: C21H30O2Intoxicating: No TypeNeutral FormulaC21H30O2 IntoxicatingNo Key focusPain & mood Cannabichromene · 314.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of CBC, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C21H30O2 and it weighs 314.5 g/mol. Pain reliefMoodAnti-inflammatoryAnti-bacterial About What is CBC? Cannabichromene, or CBC, is one of the four most common cannabinoids in cannabis, alongside THC, CBD and CBG, yet most people have never heard of it. It does not make you high. Like the others, CBC starts as an acid, CBCA, made from the mother cannabinoid CBGA, and it appears once the plant is heated. In the body How CBC Works CBC barely touches the CB1 receptor, which is why it is not intoxicating. It does switch on the CB2 receptor, and it strongly activates the body’s TRP channels, which sense pain and heat. This may be how it helps with discomfort. Laboratory research has looked at CBC for pain, mood and inflammation, and even at how it might support brain cells. Like many minor cannabinoids, it is thought to work best as part of a team, the “entourage effect”, rather than alone. Receptor snapshot Where CBC Acts The endocannabinoid system has two main receptors. Here is how strongly CBC acts on each. CB1Brain & nervous systemNone Barely touches CB1, so it is not intoxicating. CB2Immune system & bodyPartial Does activate CB2, which is linked to inflammation. Beyond CB1 and CB2: Strongly activates TRPA1 and TRPV pain and heat-sensing channels, which may be how it helps with pain. In the plant How CBC is Made CBC is made from CBCA, which the plant produces from CBGA using an enzyme called CBCA synthase. Heating turns CBCA into CBC. Over time, and with strong light, CBC can slowly change again into another cannabinoid called CBL. Comes fromCBCA→ add heat →CBC Good to know Safety and Side Effects CBC appears to be well tolerated, with little sign of serious side effects in the limited research so far. Because human studies are scarce, its long-term safety is not fully known. As always, tell your prescriber before adding a new cannabinoid to your routine. Questions CBC: Common Questions Is CBC intoxicating? No. CBC hardly binds the CB1 receptor, so it will not make you high. It is being studied for pain, mood and inflammation. What does CBC do? CBC seems to work mainly through the body’s TRP pain and heat channels, and by activating CB2 receptors. Researchers think it works best together with THC and CBD, as part of the “entourage effect”. PreviousDelta-8-THC NextTHCV Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References DeLong, G.T., Wolf, C.E., Poklis, A. and Lichtman, A.H. (2010) ‘Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by delta-9-tetrahydrocannabinol’, Drug and Alcohol Dependence, 112(1-2), pp. 126-133. doi: 10.1016/j.drugalcdep.2010.05.019. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006. Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post CBC first appeared on PatientsCann UK®.</p>

CBG: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide CBG CBG cannabigerol, “the mother cannabinoid” pronounced: kan-uh-bih-JER-ol The “mother cannabinoid” – the plant makes everything else from its acid form. Neutral cannabinoidFormula: C21H32O2Intoxicating: No TypeNeutral FormulaC21H32O2 IntoxicatingNo Key focusFocus & gut Cannabigerol · 316.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of CBG, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C21H32O2 and it weighs 316.5 g/mol. FocusAnti-bacterialGut supportAnti-inflammatory About What is CBG? Cannabigerol, or CBG, is often called the “mother cannabinoid”. That is because its acid form, CBGA, is the raw material the plant uses to build almost every other cannabinoid. Most plants turn nearly all of their CBGA into other things, so mature flower usually contains only a little CBG. To get more CBG, growers harvest some plants early, or breed special CBG-rich varieties. Like CBD, CBG does not make you high. In the body How CBG Works CBG binds both the CB1 and CB2 receptors, but only weakly, which is why it is not intoxicating. It also acts on other targets, including alpha-2 adrenoceptors, which are involved in alertness, and serotonin receptors. Early research, still mostly in the lab and in animals, is looking at CBG for inflammatory bowel disease, for protecting nerve cells, for mood, and as an antibacterial. Human studies are still limited, so its benefits are not yet proven. Receptor snapshot Where CBG Acts The endocannabinoid system has two main receptors. Here is how strongly CBG acts on each. CB1Brain & nervous systemPartial Binds CB1 weakly, so it is not intoxicating. CB2Immune system & bodyPartial Binds CB2 weakly too. Beyond CB1 and CB2: Also acts on alpha-2 adrenoceptors and blocks 5-HT1A serotonin receptors. In the plant How CBG is Made CBG comes from CBGA, the first cannabinoid acid the plant makes, by joining a molecule called olivetolic acid with a terpene building block. Any CBGA the plant does not turn into THCA, CBDA or CBCA can be heated to become CBG. This is why CBG sits at the very start of the cannabinoid family tree. Comes fromCBGA→ add heat →CBG Good to know Safety and Side Effects CBG appears to be well tolerated in the small amount of research done so far, with few reported side effects. Because studies in people are limited, its long-term safety is not fully known. As with any cannabinoid, tell your prescriber before adding CBG, especially if you take other medicines. Questions CBG: Common Questions Why is CBG called the mother cannabinoid? Because its acid form, CBGA, is the raw material the cannabis plant uses to build the other cannabinoids. Enzymes turn CBGA into THCA, CBDA and CBCA, which then become THC, CBD and CBC. Is CBG intoxicating? No. CBG binds the CB1 receptor only weakly, so it does not cause a high. PreviousCBD NextCBN Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nachnani, R., Raup-Konsavage, W.M. and Vrana, K.E. (2021) ‘The pharmacological case for cannabigerol’, Journal of Pharmacology and Experimental Therapeutics, 376(2), pp. 204-212. doi: 10.1124/jpet.120.000340. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R. (2009) ‘Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb’, Trends in Pharmacological Sciences, 30(10), pp. 515-527. doi: 10.1016/j.tips.2009.07.006. Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post CBG first appeared on PatientsCann UK®.</p>

CBN: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide CBN CBN cannabinol pronounced: kan-uh-bih-NOL The ageing cannabinoid – forms as THC gets old, often linked with sleep. Neutral cannabinoidFormula: C21H26O2Intoxicating: Mild TypeNeutral FormulaC21H26O2 IntoxicatingMild Key focusSleep Cannabinol · 310.4 g/mol The molecule Chemical structure This is the accurate skeletal structure of CBN, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C21H26O2 and it weighs 310.4 g/mol. SleepMildly relaxingPain reliefAnti-inflammatory About What is CBN? Cannabinol, or CBN, is the cannabinoid of old cannabis. The plant does not really set out to make it. Instead, it forms slowly when THC is left exposed to air, heat and light. Older, or poorly stored, cannabis tends to have more CBN. CBN is only very mildly intoxicating, far weaker than THC. It is best known for its reputation as a sleep aid, although the science behind that is thinner than the marketing suggests. In the body How CBN Works CBN is a weak activator of the CB1 receptor, roughly one-tenth as strong as THC, which is why it barely makes you high. It binds the CB2 receptor a little more strongly, linking it to the immune system. Its popular link with sleep may come partly from the other sedating compounds found in aged cannabis, rather than from CBN alone. Good-quality human studies on CBN for sleep are still needed. Receptor snapshot Where CBN Acts The endocannabinoid system has two main receptors. Here is how strongly CBN acts on each. CB1Brain & nervous systemWeak / indirect Weak CB1 activity – about one-tenth as strong as THC, so only very mildly intoxicating. CB2Immune system & bodyPartial Binds CB2 a little more strongly than CB1. In the plant How CBN is Made Unlike most cannabinoids, CBN does not come straight from CBGA. It is a breakdown product: THC slowly turns into CBN as it oxidises over time. This is why fresh cannabis has very little CBN, and why the amount rises the longer a product is stored. Comes fromDelta-9-THC→ over time →CBN Good to know Safety and Side Effects There is not much safety research on CBN by itself. Because it is mildly intoxicating, it could in theory add to the effects of THC. Few side effects have been reported, but this reflects how little it has been studied rather than proof that it is risk-free. Speak to your prescriber before using a CBN product for sleep, especially alongside other sleep medicines. Questions CBN: Common Questions Does CBN help you sleep? CBN is often sold as a sleep aid, but the research is limited. Some of its reputation may come from other compounds in aged cannabis rather than CBN itself. Speak to your prescriber before using it for sleep. Where does CBN come from? CBN is not made directly by the plant. It forms slowly when THC is exposed to air, heat and light over time, which is why older cannabis tends to have more of it. PreviousCBG NextDelta-8-THC Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References ElSohly, M.A. and Gul, W. (2014) ‘Constituents of Cannabis sativa’, in Pertwee, R. (ed.) Handbook of Cannabis. Oxford: Oxford University Press, pp. 3-22. Morales, P., Hurst, D.P. and Reggio, P.H. (2017) ‘Molecular targets of the phytocannabinoids: a complex picture’, Progress in the Chemistry of Organic Natural Products, 103, pp. 103-131. doi: 10.1007/978-3-319-45541-9_4. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post CBN first appeared on PatientsCann UK®.</p>

Delta-9-THC: What It Is, Effects and Safety | PatientsCann UK Skip to main content Back to Cannabinoids Guide THC Delta-9-THC delta-9-THC, dronabinol pronounced: DEL-tuh nine tet-ruh-hy-droh-kuh-NAB-ih-nol The main active cannabinoid – the one that makes you feel “high”. Neutral cannabinoidFormula: C21H30O2Intoxicating: Yes TypeNeutral FormulaC21H30O2 IntoxicatingYes Key focusPain & nausea Delta-9-tetrahydrocannabinol · 314.5 g/mol The molecule Chemical structure This is the accurate skeletal structure of Delta-9-THC, drawn from PubChem data. Each corner and line-end is a carbon atom, and the red O marks oxygen. Its formula is C21H30O2 and it weighs 314.5 g/mol. Pain reliefAppetiteAnti-sicknessEuphoria About What is Delta-9-THC? Delta-9-THC is the most famous cannabinoid, and the one that makes cannabis feel intoxicating. It was first identified by scientists Raphael Mechoulam and Yechiel Gaoni in 1964. When people talk about how “strong” a cannabis product is, they usually mean how much THC it contains. The fresh plant does not actually hold much THC. It makes an acid called THCA instead. THC only appears once the plant is dried, then heated, vaped or smoked. This is why the THC number on a lab report tells you how much becomes available after heating. In the body How THC Works THC works by fitting into the CB1 receptor, which sits mostly in the brain and nervous system. Switching CB1 on changes how nerve cells pass messages. This is what causes the “high”, and it is also how THC eases pain, calms nausea and brings on hunger. THC acts on CB2 receptors too, which are linked to the immune system. UK specialists may consider a THC-containing medicine for problems such as long-term pain, muscle spasms in multiple sclerosis, and sickness from chemotherapy, when licensed treatments have not helped. The right amount is very personal, so prescribers usually start low and go slow. Receptor snapshot Where THC Acts The endocannabinoid system has two main receptors. Here is how strongly Delta-9-THC acts on each. CB1Brain & nervous systemStrong Switches on CB1 in the brain and nerves. This is what causes the “high”, and also eases pain, nausea and appetite loss. CB2Immune system & bodyPartial Also activates CB2 on immune cells, which is linked to inflammation. In the plant How THC is Made THC begins life as THCA, its raw acid form, which the plant builds from the “mother” cannabinoid CBGA. THCA on its own is not intoxicating. Heat removes a small piece of the THCA molecule (a carbon dioxide group) and turns it into THC. This step is called decarboxylation. Later, as cannabis ages and meets air and light, THC slowly changes again into CBN. Comes fromTHCA→ add heat →Delta-9-THC Good to know Safety and Side Effects THC can cause a fast heartbeat, dry mouth, red eyes, dizziness, and feelings of anxiety or paranoia, especially at higher doses or in people who are new to it. It affects your ability to drive and use machinery. It is not recommended in pregnancy, and heavy long-term use can lead to dependence in some people. If you ever take too much and feel unwell, find a calm space, sip water, and wait it out; the feeling passes. Always follow your prescriber’s dose and never mix your medicine with alcohol or other drugs without advice. Questions Delta-9-THC: Common Questions Will THC get me high? Yes. Delta-9-THC is the cannabinoid responsible for the “high” feeling. This happens because it switches on CB1 receptors in the brain. The amount you feel depends on the dose, the product and your own tolerance. Is THC legal in the UK? THC is a controlled drug, but since November 2018 specialist doctors can legally prescribe cannabis medicines that contain THC. You cannot buy high-THC products legally without a prescription. PreviousCBGA NextCBD Back to full Cannabinoids Guide Important: This page is for education only. It is not medical advice. Cannabinoid research is still developing, and many studies have been done in cells or animals rather than people. Always speak to your prescriber before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Gaoni, Y. and Mechoulam, R. (1964) ‘Isolation, structure, and partial synthesis of an active constituent of hashish’, Journal of the American Chemical Society, 86(8), pp. 1646-1647. doi: 10.1021/ja01062a046. Pertwee, R.G. (2008) ‘The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-9-tetrahydrocannabivarin’, British Journal of Pharmacology, 153(2), pp. 199-215. doi: 10.1038/sj.bjp.0707442. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 29 July 2026).

<p>The post THC first appeared on PatientsCann UK®.</p>

PatientsCann UK | Already vaped medical cannabis (AVB): a practical guide Skip to content Legal & Support AVB / ABV General information Already vaped medical cannabis (AVB): a practical guide for patients Many patients who lawfully use prescribed cannabis flower in a dry-herb vaporiser ask what to do with the material left behind after vaping. It is often called already vaped bud (AVB), or already been vaped (ABV). There is very little official guidance on the subject, but the law does provide some helpful answers. PatientsCann UK Legal & Support Plain-English guide On this page What the law says Is AVB lawful? Good practice Why keep AVB? A sensible approach General information, not legal advice This guide explains how the current law appears to apply. It is not legal advice, the law may change over time, and every patient’s circumstances are different. The short answer No duty to destroy Nothing in the law requires you to destroy cannabis the moment it has been vaporised. No time limit There is no set limit on how long lawfully prescribed cannabis may be kept. No container rule Your medication does not have to stay in its original dispensing container at all times. Quick reader poll Be honest: what happens to your AVB? A quick, anonymous poll for community interest. One tap and you are done. What do you do with your already vaped bud? Bin it right away Straight in the bin, no ceremony. Feed it to the soil Compost it and let the garden say thanks. Store it and forget it It is in a jar somewhere. Probably. Save it to re-use Waste not, want not. Dispose of it at a pharmacy Hand it in at a local community pharmacy for safe disposal. Not applicable, I do not use flower No dry-herb vaping, so no AVB to deal with. I am happy to share my anonymous answer with PatientsCann UK. Cast my vote Please note. This poll is for community interest only and is completely anonymous. It is not medical or legal advice. Whatever your answer, keep following your prescriber’s directions. Unwanted medicine can be handed in at a local community pharmacy for safe disposal, as pharmacies in the UK accept unwanted medicines from private households as part of their NHS essential services. Thanks for voting! Your answer is in, and it stays anonymous. However you handle your AVB, remember to follow your prescriber’s directions. Unwanted medicine can be handed in at a local community pharmacy for safe disposal. The legal position What does the law say? Prescribed cannabis is a controlled drug Cannabis-based products for medicinal use (CBPMs) prescribed by a specialist doctor are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. The Misuse of Drugs Act 1971 makes it unlawful to possess a controlled drug unless you are authorised to do so. For patients, that authority comes from the Misuse of Drugs Regulations 2001, once the medicine has been lawfully prescribed and supplied to you. What the legislation does not say Importantly, there is no provision in the legislation that: requires patients to destroy cannabis immediately after it has been vaporised; imposes a time limit on how long prescribed cannabis may be possessed; or requires medication to remain in its original dispensing container at all times. The key question Does AVB remain lawful? There is currently no reported UK court decision dealing specifically with already-vaped prescribed cannabis. However, AVB originates from medication that has been lawfully prescribed and supplied. The legislation does not say that it becomes unlawful simply because it has been heated in a vaporiser. While no definitive legal ruling exists, there appears to be no statutory requirement to dispose of it immediately after use. AVB starts life as lawfully prescribed medicine. Nothing in the legislation says it stops being lawful the moment it has been heated. PatientsCann UK, Legal & Support Sensible habits Good practice Although the law does not specifically require it, a few simple habits can make the origin of your AVB clear if anyone ever asks. Patients may wish to do the following. 1 Keep your prescription or dispensing label Hold on to your current prescription, or the label from your dispensed medication. 2 Carry proof of identity when travelling If you travel with your medication, keep proof of identity with you. 3 Reuse the original container If you are keeping AVB for later disposal, store it in the original empty dispensing container where practical. 4 Keep it separate Avoid mixing AVB with non-prescribed cannabis or any other substance. Why this helps. Together, these steps help show that the material came from medication lawfully prescribed to you, should any question ever arise. Everyday reasons Why might someone keep AVB? Some patients hold on to AVB for a short time before disposing of it, for entirely everyday reasons, including: convenience; waiting until they are home before disposing of it; or collecting it so it can be disposed of safely in one batch. Safe disposal is a genuine reason to hold on to it. The NHS advises that unwanted medicine should be returned to a pharmacy for safe disposal rather than put in household waste, so keeping AVB until you can hand it in is a responsible thing to do. The law does not distinguish between these situations. Keeping AVB briefly for any of these reasons is treated no differently from keeping it for any other. Putting it together A sensible approach Keep following your prescriber’s directions on how to use your medication. If you do keep AVB, a clearly labelled container that links it to your prescription can help show where it came from. Keep it separate from your fresh medication, though: returning AVB to a bottle that still holds unused flower can affect your dosing and contaminate medicine you have not yet used. None of this appears to be a legal requirement, but it is simple and sensible. In summary The bottom line Current UK legislation does not appear to

<p>The post Already Vaped Bud (AVB) first appeared on PatientsCann UK®.</p>

A plumber, a prescription, and a fair hearing at work | PatientsCann UK Skip to content Patient Story A plumber, a prescription, and a fair hearing at work When Dean Carroll told his employer he had been prescribed medical cannabis, he expected a fight. Instead he got a fair, individual assessment and kept the safety-critical job he loves. He wants other patients to know it can be done. DC Dean CarrollPlumber, supervisor & PatientsCann UK volunteer Cheshire, UK Housing association Dean Carroll — plumber, supervisor and PatientsCann UK volunteer, Cheshire. Dean Carroll is a plumber and supervisor for a housing association. He is also one of the estimated tens of thousands of people in the UK who hold a legal prescription for medical cannabis. When those two facts met at work, the result was not the one many patients fear. Rather than wait to be found out, Dean chose to be open. He told his employer about his prescription up front. Because his job is safety-critical, he was asked to attend an occupational health assessment to check whether he could keep doing it safely. It is exactly the kind of moment that stops many patients from ever telling their employer at all. What happened next, Dean says, should be the template for how these situations are handled. He has since joined PatientsCann UK as a volunteer, and he is sharing his experience so that other patients, and the employers who manage them, can see that a prescription need not be the end of a career. The fact that I am prescribed medical cannabis did not automatically mean I was considered unfit to work. The assessment focused on my individual circumstances and my ability to do my role safely. — Dean Carroll How it was handled What good practice looked like Dean’s employer and occupational health team followed a clear, methodical process. Each step looked at the real question: can this person do this job safely? Here is how it unfolded. 1 Dean disclosed his prescription He proactively told his employer he had been prescribed medical cannabis, rather than keeping it hidden. Because his role is safety-critical, an occupational health assessment was arranged. 2 He shared the clinical detail Dean provided information on his prescribed dosage, the potential effects and the impairment window after dosing, and any other medication he was taking, so the assessment was based on facts, not assumptions. 3 Occupational health assessed his fitness to work The assessment concluded there were no concerns about Dean’s ability to carry out his work safely, including the driving that forms part of his role. 4 A workplace risk assessment considered the real duties His employer then assessed the specific risks tied to his role. Dean also supplied guidance from his medical cannabis clinic on the current UK position on driving while prescribed. 5 Dean kept his job Following the assessment and a sensible risk-management plan, Dean was able to carry on in his role. Safety standards were maintained, and a skilled employee was retained. The risk assessment looked squarely at the demanding parts of the job, not at the label on his prescription: Power tools Lone working Working at height Driving The way my employer and occupational health team handled my situation should be seen as an example of good practice. It was professional, thorough, and, most importantly, I felt listened to and understood. — Dean Carroll Clearing up the confusion A prescription is not an automatic barrier Dean hopes his story challenges some stubborn misconceptions. Being prescribed medical cannabis should not, on its own, be treated as a bar to employment or career progression. What matters is the individual, their medication, and the honest requirements of the role. Judge the person, not the label Assess someone’s actual ability to work safely, not an assumption based only on the fact of a prescription. Open communication works Disclosing early let Dean explain his dosage, his effects, and when they occur, so decisions rested on facts. Safety is not compromised A proper risk assessment lets employers support staff while still holding appropriate health and safety standards. My experience has shown me it is possible to take medical cannabis seriously as a medication, take workplace safety seriously, and still support an employee to do their job to the best of their ability. — Dean Carroll Dean is clear that he is not asking for special treatment, only for a fair and individual hearing. There are, he points out, many patients across the UK who are prescribed medical cannabis and who are fully capable of working, contributing, and carrying out their roles safely. He hopes that by speaking up, he can encourage more open conversation between patients, employers and occupational health professionals, and help others feel able to disclose without fear of losing the work they depend on. This is one patient’s personal experience, shared to support others. It is not legal or employment advice, and every workplace is different. For your rights at work, see our Employment guide, and read the current UK position on driving while prescribed. Over to you Have you been through something similar? Tell us. Real stories change minds. Whether your experience at work, or anywhere else, was positive like Dean’s or a good deal harder, sharing it helps other patients feel less alone and helps us push for fairer treatment. Tell us as much or as little as you like. Share your story Fields marked with an asterisk are required. Please do not include medical records or other patients’ details. We will never publish anything without asking you first. Thank you for sharing your story. We have received it and a member of our team will be in touch. Your words help other patients feel understood. Your name * Email address * Only used to reply to you. Your job or situation (optional) What is your story about? Please select…Employment or the workplaceOccupational health or safety-critical workDrivingHousingTravelStigma or discriminationA positive experienceSomething else Your story, in your own words

<p>The post A plumber, a prescription, and a fair hearing at work first appeared on PatientsCann UK®.</p>

PatientsCann UK | Free the weed? The case for self-sustainability Skip to content News Cannabis policy Patient view Free the weed? A new campaign, and the case for self-sustainability Legal Growers UK has launched a national campaign for a regulated British cannabis model. We report what it proposes, set out why we think patients should be able to grow their own, and ask you one simple question: legalisation, or decriminalisation? PatientsCann UK News and Advocacy 21 July 2026 On this page The campaign The blueprint Our view The evidence Your view References Where this article stands We are reporting on a campaign run by Legal Growers UK, an organisation we are not part of. We share it so patients can read it and make up their own minds. This is not legal or medical advice, and it is not an endorsement of any party or campaign. Why this matters The market never left The campaign argues prohibition did not remove the cannabis trade. It handed control to an illegal market that checks no age, tests no product, and pays no tax. Patient access Many patients tell us a legal prescription can work well, but the cost of it puts safe, legal medicine out of their reach. Self-sustainability Our own belief is plain: patients should have a route to grow their own, safely and legally, at home. The news A national campaign for a regulated British model On Friday 17 July 2026, Legal Growers UK launched a national campaign for what it calls a careful, safe British model for regulating cannabis. The group is a not-for-profit, run by volunteers from across the United Kingdom.1 Its argument is short. Prohibition has not made cannabis go away. Instead, the campaign says, the trade has been left in the hands of an illegal market that does not check age, does not test its product, and does not pay tax. It wants cannabis placed under clear, enforceable rules so that government, police, and local councils have better tools to keep the public safe. The campaign hashtag is #LegalGrowersNotTraffickers. To meet the public face to face, the volunteer team is at Borofest 2026, the Borofest Glass Festival, which runs from 17 to 20 July at Overstone, Northampton. The organisation says it is a growing team and welcomes new volunteers and supporters. The country is hurting. Our streets and schools are no longer safe, patients have poor access, and it is a drain on the public purse when other countries have profited to the tune of billions. Dan Balderson, Chief Executive, Legal Growers UK The detail What the campaign proposes Rules to protect people Sales to adults only, with strict age verification. Plain packaging, free of cartoon-style designs. Outlets kept away from schools and playgrounds. Products laboratory-tested and labelled with their exact strength. Employers keep the right to require staff to be sober and fit for duty. Fairness and funding Lawful use in a person’s own private time protected. Councils given clearer powers over nuisance such as smoke or smell. Old, minor cannabis records cleared automatically. A share of tax revenue directed to NHS mental health services, youth education, and enforcement. These are the campaign’s own proposals, summarised in plain terms. We set them out so you can weigh them up, not to tell you whether to back them. Our view The case for self-sustainability Here is where we do take a side, and we are clear about it. PatientsCann UK believes that patients should be able to look after their own health. For some, that includes the right to grow a small amount of their own medicine at home. We call this self-sustainability. The reason is simple, and it comes straight from patients. A prescription can be safe and effective, but many people cannot afford one. When the legal route is too expensive, patients are pushed towards a market they cannot trust, or they go without. Growing your own is low cost, it keeps money away from organised crime, and it puts a patient back in control of their own care. This is not a call to ignore safety. It is a call to give patients a fair, legal path to self-sustainability, whatever wider route the country chooses. On that narrow point, we support the spirit of freeing the plant, so that the people who rely on it are no longer treated as criminals. It aligns with all my values: community safeguarding, and people like me cannot afford a prescription. My initials are GYO, Grow Your Own, and it is about time. Gary Youds, Chillin’ Rooms Owner and Legal Growers UK Board Member The evidence What the international research shows The campaign points to evidence from abroad. A second annual evaluation of Switzerland’s regulated cannabis pilot trials, produced for the Swiss Federal Office of Public Health and published in November 2025, found that controlled legal access moved adult buyers away from the illegal market. It recorded no negative effects on public order or health to date.2 Legal Growers UK cites this as international evidence, and does not claim the Swiss model is the same as its own plan. We would add our own note of care: one country’s pilot is not proof for another, and early findings like these should be read carefully, not treated as a promise. Read evidence with care. Early results from one country’s trial cannot tell us exactly what would happen in Britain. They are a signal worth studying, not a guarantee. Over to you Legalisation or decriminalisation. Where do you stand? Choose your stance: legalisation, decriminalisation, or still deciding These two words often get used as if they mean the same thing. They do not. Pick the one closest to your view to see what it would mean in plain terms, then submit your answer. Responses are anonymous, and no personal details are collected. Legalisation Legal to grow, buy and sell, under strict rules Decriminalisation No criminal record for personal use, supply stays illegal Still deciding I want to weigh

<p>The post Free The Weed? first appeared on PatientsCann UK®.</p>

PatientsCann UK | What the McCarthy Tribunal Decision Really Says Skip to content News & Analysis Workplace Rights Driving & the Law What the McCarthy tribunal decision really says about medical cannabis, driving and work Reduced to a headline, this case looks like a ruling that medical cannabis patients cannot work or drive. That is not what the tribunal decided. Here is what the judgment in Miss L McCarthy v Kirklees Metropolitan Council actually found, and what it means for patients and employers. PatientsCann UK News & Advocacy Employment tribunal analysis On this page Context Not a blanket ban Treated differently? Missing information Occupational health Where it went wrong The wider lesson The reporting problem Bottom line Letter template References Please note This article is general information and analysis of a published employment tribunal decision. It is not legal or medical advice. If you face a workplace or driving issue involving your prescription, seek advice specific to your circumstances. Why this matters Not a blanket ban The tribunal did not find that patients are automatically unfit to work or drive. A narrow question It was about one claimant, in a safety-sensitive role, against a specific background. Misreported Headlines framing this as “cannabis means you cannot work” distort the judgment. Background Context: why this case has caused concern At first glance, the tribunal decision in Miss L McCarthy v Kirklees Metropolitan Council looks like exactly the sort of case the medical cannabis community has feared: a patient has a lawful medical cannabis prescription, wants to return to work, and the outcome appears to suggest that medical cannabis use means you cannot safely work or drive as part of your job. Read through that lens, and reduced to a newspaper headline, it is easy to see why people are worried. But that is not what the tribunal actually decided. The important distinction is that the tribunal did not find that medical cannabis patients are automatically unfit for work or unable to drive. It found that, in this particular situation, the employer was entitled to pause and seek further information before allowing a full return to normal duties, because the job involved vulnerable service users and some driving, and because the employer did not yet have enough role-specific and prescription-specific information to complete its safety assessment. The claimant had a diagnosis of Emotionally Unstable Personality Disorder / Borderline Personality Disorder, which the employer knew about. She had also experienced a serious mental-health crisis in September 2023, had been admitted to psychiatric hospital, and was absent from work. During this period, she also disclosed previous illegal drug use, including cocaine and cannabis. She later obtained a private medical cannabis prescription, and provided her employer with some information about medical cannabis, including clinic correspondence and external guidance. At around the same time, the employer received a PIPOT safeguarding referral involving alleged aggressive or threatening behaviour reported through NHS and police channels. Because the claimant worked with vulnerable service users, the employer treated this as a significant safeguarding issue and required a further enhanced DBS check. So the tribunal was not looking at a simple question of “can someone prescribed medical cannabis work and drive?” It was looking at a much narrower question: was this employer acting unlawfully when it paused, asked for more information, sought occupational-health advice, considered safeguarding concerns, and managed a staged return to work in this specific set of circumstances? The tribunal answered no. The key point This was not a blanket ban case A central concern is that the decision might create a precedent that employers can say “there is not enough information about medical cannabis, so we cannot safely let you drive.” But that is not what the tribunal found. The claimant alleged that she was told in April 2024 that she could not drive as part of her duties. The tribunal rejected that allegation. It found that no driving prohibition was imposed. There had been discussion about medical cannabis, driving law, and the statutory defence where medication is prescribed and taken as directed, but the tribunal found the employer did not ban her from driving. That is important. The case does not stand for the proposition that an employer can automatically prevent a medical cannabis patient from driving for work. It stands for the much narrower proposition that, where there are specific safety-related questions, an employer may ask for relevant information before reaching a decision. UK driving law also does not impose a blanket ban on people taking prescribed medicines. GOV.UK explains that a person may drive after taking certain prescribed medicines if they have been prescribed them, have followed healthcare advice, and the medicine is not causing them to be unfit to drive. The lawful position. Not “medical cannabis equals no driving,” but rather: a patient may drive if the medicine is lawfully prescribed, taken as directed, and they are not impaired or unfit to drive. Discrimination argument Why the tribunal did not see this as cannabis being treated differently The claimant argued that the employer had no business asking about her driving while taking prescribed medication, and that other medicines were not treated in this way. The tribunal rejected that argument. It accepted evidence from HR that similar enquiries would be made if any employee’s prescribed medication was suspected to affect their ability to perform their duties safely. This is the crucial distinction. The tribunal did not say “medical cannabis is uniquely risky, so employers can restrict it.” It said, in effect, if any medication may affect safe performance in a particular role, the employer can make proportionate enquiries. That matters because many prescribed medicines can affect driving, judgement, alertness, coordination, or reaction time, for example opioids, benzodiazepines, sedatives, strong painkillers, some psychiatric medications, and other controlled medicines. GOV.UK’s drug-driving guidance is framed around impairment and prescribed medicines generally, not medical cannabis alone. The problem would be different if an employer scrutinised medical cannabis patients but ignored comparable risks from other prescribed medicines. That could potentially

<p>The post McCarthy Tribunal Decision first appeared on PatientsCann UK®.</p>

Case study REX v Saleem Aziz Acquitted Cleared in court: a medical cannabis patient’s drug driving appeal Sal Aziz was stopped by police, charged, and convicted. Then the Crown Court overturned it. Here is what happened, what the law really says, and what it means for patients, police, lawyers, and the courts. PatientsCann UK Drug driving and the medical defence Winchester Crown Court, 10 February 2026 Read the full report (PDF) On this page The story What happened The law Four myths Medical and science The evidence Why it was won What is broken Guidance Case file References This is not legal or medical advice This is a personal account and a public resource, based on real case papers, public reports, and the author’s understanding of the law. If you face a drug driving charge, get advice from a qualified solicitor and your medical team where you can. This case is a strong example, but every case turns on its own facts and evidence. The case at a glance Blood THC 3.6 micrograms per litre of blood, over the 2 microgram limit. Charges Two, under sections 4 and 5A of the Road Traffic Act 1988. Hearings Three court hearings before the right result was reached. Outcome Cleared. The conviction was overturned at the Crown Court. Overview The story in short Sal Aziz is a patient who is legally prescribed medical cannabis. In March 2024, police stopped the car he was driving as friends were being taken home from an event. He passed the roadside alcohol test. He told the officer straight away that he was a prescribed patient. A roadside drug swab showed cannabis, and he was asked to do a set of roadside tasks called a Field Impairment Test. He was arrested. A blood test later showed 3.6 micrograms of THC per litre of blood. The legal limit is 2 micrograms per litre. He was charged under two parts of the Road Traffic Act 1988: section 4 (driving while unfit) and section 5A (driving over the drug limit). The magistrates’ court dropped the section 4 charge but found him guilty of the section 5A offence. He was fined and banned from driving for 36 months. He appealed. On 10 February 2026, at Winchester Crown Court, Sal Aziz was cleared. The prosecution could not prove, beyond reasonable doubt, that his medical defence did not apply. The prosecution had argued his medicine was unlawful because more than 30 days had passed since the prescription, and because it was past its labelled use-by date. The court rejected this. The pharmacist expert, Umesh Chauhan, agreed that the “30 days” idea is best-practice guidance, not criminal law. The judge compared it to drinking milk after its best-before date. Passing the date does not make it unlawful to use. Crown Court reasoning, as described in the report Step by step What happened 1 About seven months before the stop A separate police encounter about his prescribed cannabis caused him serious distress. NHS notes record shaking, anxiety, and a hospital visit. Police contact was a known trigger for his physical symptoms. 2 31 March 2024: the stop On the A303, his car was stopped as part of an operation on vehicles leaving an event. There was no crash and no problem with his driving. The officer noted that he seemed nervous and shaky. 3 The roadside tests The alcohol breath test was negative. The roadside drug swab showed cannabis. He told the officer at once that he was a prescribed patient. He was then asked to do the Field Impairment Test: an eye check, a balance test, walking in a line, and touching his nose. 4 The arrest The officer treated the shaking and balance problems as signs of drug impairment. But these are also listed in his medical notes as symptoms of anxiety. He was arrested and his prescribed cannabis, in its labelled packet, was found. No proper interview about his condition took place. He was released to wait for blood results. 5 The blood result The blood test showed 3.6 micrograms of THC per litre of blood. This was over the 2 microgram limit. Nothing else was found. 6 The magistrates’ court The section 4 (unfit) charge was dropped. He was convicted of the section 5A (over the limit) charge. The court wrongly accepted that the medical defence did not apply because the medicine was “expired” or used beyond 28 to 30 days. He was fined and banned from driving for 36 months. 7 The appeal He appealed to the Crown Court, arguing that the medical defence applied. He brought prescription records, NHS notes, expert pharmacist evidence, and the science on THC. 8 10 February 2026: the result The appeal was allowed. The conviction was overturned. The prosecution had not disproved the medical defence. Plain English The law, in plain words Two parts of the Road Traffic Act 1988 matter here. They ask different questions, and it helps to keep them apart. Section 5A: over the drug limit It is an offence to drive with a named drug above a set limit in your blood. For cannabis, the limit is 2 micrograms of THC per litre of blood. This is a strict offence: the prosecution does not have to prove your driving was actually affected. The limit is set by the Drug Driving (Specified Limits) (England and Wales) Regulations 2014. Section 4: unfit through drugs This is a different offence. Here the prosecution must prove that your driving was actually impaired, and that a drug caused that impairment. This usually rests on observations, the Field Impairment Test, and expert evidence. The medical defence (section 5A(3)) If you are a lawful patient, you have a defence to the section 5A offence. You need to show three things. 1 It was prescribed or supplied for a medical reason For a medical or dental purpose. Self-medication or illegal use does not count. 2 You took it as directed This means following advice about driving after use,

<p>The post Drug Driving and the Medical Cannabis Defence first appeared on PatientsCann UK®.</p>

PatientsCann UK | Patient coalition appeal over plans to restrict CBD Press release Patient rights Patient groups across Europe launch an appeal over plans to restrict CBD A group of patient organisations, including PatientsCann UK®, has launched a public appeal and petition. They are worried about plans in the Czech Republic to treat CBD as if it were a chemical used to make illegal drugs. Their message is short: share the evidence, talk to the patients affected, and decide in the open. Sign the appeal PatientsCann UK® Coalition press release Prague, 17 June 2026 On this page In short Why it matters What we are asking Sign the appeal About the coalition References PatientsCann UK® is one of eight patient organisations in this coalition. The coalition campaigns on health policy and patient rights. It does not sell, promote, or link to any CBD product. In short What is happening Patient groups across Europe and beyond have launched a public appeal and petition called Care Before Discrimination is a Human Right. The worry Czech officials may treat CBD as a drug precursor, a chemical used to make illegal drugs, and limit how it can be handled. Not a ban on rules The coalition backs safety testing, honest labels, age limits, and real action against dangerous products. The ask Share the evidence, talk to the patients affected, and decide openly. You can add your name to the appeal. The background Why it matters CBD (cannabidiol) is a substance from the cannabis plant. It does not make a person feel high. On its own, it is not controlled under the main international drug laws. A purified CBD medicine is already approved across the European Union to treat severe forms of epilepsy, a condition that causes seizures. Because of this, the coalition says a sweeping restriction needs strong evidence behind it. It points to the International Narcotics Control Board, the United Nations body that watches drug controls. By that board’s own account, the proof that CBD is used to make illegal lab-made cannabinoids is limited. There is also a practical worry. The products that are truly risky are synthetic and semi-synthetic cannabinoids, which are part or fully man-made cannabis-like chemicals, often sold through grey-market channels. These need direct enforcement, age limits, and quality rules. The appeal is published just hours before the Czech Government’s Council for Addiction Policy meets on the afternoon of 17 June 2026. The unintended risk. If safe, tested CBD is pushed out of legal shops, demand will not disappear. It will move to an unregulated market, where contamination with heavy metals, pesticides, and solvents is far harder to catch. Patients aren’t asking for a loophole. We’re asking not to be pushed into the shadows. If the Government believes CBD should be restricted, show the evidence, listen to the patients it affects, and explain why the rules we already have aren’t enough. Care before discrimination means deciding in daylight. Pavel Kubů, KOPAC (Patient Association for Cannabis Treatment), Czech Republic What the coalition supports Clear quality standards. Testing for harmful substances. Honest labelling. Age limits. Real enforcement against dangerous synthetic products. What it is not asking for This is not a campaign against regulation, and it is not a request for a loophole. What the coalition objects to is a quiet, paperwork-only shortcut that rests on evidence no one has published. The appeal What we are asking The appeal calls on the Czech Government, European Union institutions, and United Nations drug-control bodies to: 1 Publish the evidence Share the proof before any CBD restriction is brought in. 2 No quiet shortcuts Avoid hidden or paperwork-only measures that skip public scrutiny. 3 Respect patient choice Respect patients’ freedom, dignity, and right to make informed decisions. 4 Regulate, do not ban Set fair and measured rules rather than a blanket prohibition. 5 Target the real risk Aim enforcement at dangerous synthetic and semi-synthetic products. 6 Consult patients first Talk to patient organisations before decisions are made. Add your name to the appeal The petition is open now. The full appeal, the evidence behind it, and the press kit are on the campaign site. The appeal is published in six languages. Sign the appeal Read the full appeal Who we are About the coalition Care Before Discrimination is a Human Right is an open coalition of patient organisations, with more joining. It campaigns on health policy and patient rights, and it does not promote, sell, or link to any CBD product. The appeal’s full title is “Care Before Discrimination: Patients’ Rights and the Proposed Restriction of CBD”. Aube Canada Centrum Paraple Czech Republic Dosemociones Spain Fuck Cancer Czech Republic HARP, Human Application Research Program Czech Republic KOPAC Czech Republic PatientsCann UK® United Kingdom Verein Medcan Switzerland Coalition media contact media@cbdhumanright.org Spokespeople are available in English, Czech, Spanish, French, German, and Italian. The team replies within a working day, and faster around procedural deadlines. PatientsCann UK® press press@patientscann.org.uk For media enquiries about PatientsCann UK® and our part in the coalition. Note The appeal is available in six languages (English, Czech, Spanish, French, German, and Italian) on the campaign site and in the downloadable press kit. In the Kanavape case, the European Union’s top court held that a member state may not ban the sale of CBD lawfully produced in another member state unless a restriction is necessary and proportionate, meaning fair and no more than is needed. The CBD in that case was produced in the Czech Republic. HHC, a semi-synthetic cannabinoid, was added to Schedule II of the 1971 Convention on Psychotropic Substances by the United Nations Commission on Narcotic Drugs. The decision took effect on 6 December 2025. The primary sources behind the appeal are listed in full below. References References follow the Harvard style. Sources with no named author are listed by the responsible body. All links were checked on 17 June 2026. 1World Health Organization (2018) Cannabidiol (CBD): critical review report. Expert Committee on Drug Dependence, fortieth meeting, Geneva, 4 to

<p>The post Care Before Discrimination first appeared on PatientsCann UK®.</p>

From menstrual pain to menopause, endometriosis to anxiety, a growing body of research and real patient experience is reshaping how women access and use prescribed cannabis in the UK.

<p>The post Medical Cannabis Women’s Health first appeared on PatientsCann UK®.</p>

Eudesmol – PatientsCann UK Skip to main content Back to Terpenes Guide Eudesmol beta-Eudesmol pronounced: YOO-dez-mol A sweet, woody terpene from eucalyptus. Early research looks at appetite and blood vessels. Oxygenated sesquiterpene Boiling point: 295°C Terpene type Oxygenated sesquiterpene Boiling point 295°C Primary aroma Woody Key effect Appetite Aroma profile How it Smells The aroma of Eudesmol is described as: SweetWoodyWaxyBalsamEarthy Found naturally in: Eucalyptus, cypress, ginger, balsam, certain conifers Effects Linked Effects Boosts appetiteProtects blood vesselsAnti-tumour research These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Eudesmol? Eudesmol is a sweet, woody terpene with a slightly waxy, balsam-like smell. It is found in eucalyptus, in cypress and ginger, and in the resin of some conifer trees. It comes in a few closely related forms, with beta-eudesmol being the best studied. It is a heavy, oxygen-carrying sesquiterpene, so it tends to stay behind in heated products rather than lifting off quickly. Effects in detail What the Research Says Beta-eudesmol has been studied in the laboratory for several effects. Some animal work suggests it may affect appetite, and other studies have looked at how it acts on blood vessels and at possible anti-tumour activity (Nuutinen, 2018). All of this is early research in cells and animals. None of it is proof of benefit in people, and it should not guide treatment choices. Everyday sources Where You Find it in Daily Life You meet eudesmol in eucalyptus and cypress, in ginger, and in balsam resins. These plant oils are its richest everyday sources. Its warm, woody smell means it is used in perfumery and in some traditional herbal preparations. Research Key Studies Nuutinen (2018) reviewed the laboratory evidence on eudesmol, including its effects on appetite and blood vessels and the early anti-tumour research. Its chemistry is recorded in public databases (National Center for Biotechnology Information, 2025). Human studies are still needed. PreviousGuaiol NextMyrcene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Eudesmol first appeared on PatientsCann UK®.</p>

Caryophyllene-oxide – PatientsCann UK Skip to main content Back to Terpenes Guide Caryophyllene-oxide Caryophyllene oxide pronounced: kair-ee-oh-FIL-een OX-ide A woody, sweet terpene made when caryophyllene meets oxygen. The smell sniffer dogs are trained to find. Oxygenated sesquiterpene Boiling point: 279°C Terpene type Oxygenated sesquiterpene Boiling point 279°C Primary aroma Woody Key effect Germ-fighting Aroma profile How it Smells The aroma of Caryophyllene-oxide is described as: WoodySweetSpicyDryEarthy Found naturally in: Cloves, hops, rosemary, eucalyptus, black pepper, lemon balm Effects Linked Effects Fights fungusEnergisingUsed by detection dogs These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Caryophyllene-oxide? Caryophyllene-oxide is what you get when the well-known terpene beta-caryophyllene reacts with oxygen. It keeps a woody, spicy smell but turns a little sweeter and drier. It is found in cloves, hops, rosemary and eucalyptus. It is a heavier, oxygen-carrying sesquiterpene, so it does not evaporate as fast as the light citrus terpenes (Booth and Bohlmann, 2019). Effects in detail What the Research Says Caryophyllene-oxide is the chemical that drug-detection dogs are trained to smell, because it is a steady marker found in cannabis. In the laboratory it has been studied as an anti-fungal and for its effects on blood platelets (Nuutinen, 2018). These findings come from cell and animal studies. They are interesting starting points rather than proven treatments. Everyday sources Where You Find it in Daily Life You meet caryophyllene-oxide in cloves, in hops, in rosemary and in eucalyptus. It also forms slowly when foods and oils that contain caryophyllene are stored and exposed to air. Its warm, woody smell means it appears in perfumes and in some food flavourings. Research Key Studies Nuutinen (2018) reviewed the laboratory work on caryophyllene-oxide, including its anti-fungal activity and its effect on blood platelets. Its chemistry is recorded in public databases (National Center for Biotechnology Information, 2025). As ever, human evidence is still being gathered. Previousγ-Elemene NextHumulene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Caryophyllene Oxide first appeared on PatientsCann UK®.</p>

γ-Elemene – PatientsCann UK Skip to main content Back to Terpenes Guide γ-Elemene gamma-Elemene pronounced: EL-uh-meen A sweet, dry, fruity scent found in myrrh. Studied in the laboratory for possible anti-cancer effects. Sesquiterpene Boiling point: 252°C Terpene type Sesquiterpene Boiling point 252°C Primary aroma Sweet Key effect Anti-cancer research Aroma profile How it Smells The aroma of γ-Elemene is described as: SweetFruityDryWoodySpicy Found naturally in: Myrrh, celery, mint, lemongrass, certain spices Effects Linked Effects Studied for anti-cancerAnti-inflammatory These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is γ-Elemene? Gamma-elemene is a larger terpene with a sweet, dry, slightly fruity smell. It is part of the scent of myrrh, an old resin used in incense and medicine for thousands of years, and it also appears in celery and mint. It is a sesquiterpene, so it is heavier than the light citrus and pine terpenes and tends to stay in heated cannabis products longer. Effects in detail What the Research Says Gamma-elemene belongs to the elemene family, which has drawn real scientific interest for cancer research. A close relative, beta-elemene, is studied in some countries as part of cancer care, and laboratory work has explored how elemenes affect tumour cells (Nuutinen, 2018). It is very important to be careful here. This research is at the laboratory stage for gamma-elemene, and nothing on this page is a treatment or a cure. Anyone with cancer should follow the advice of their medical team. Everyday sources Where You Find it in Daily Life You meet gamma-elemene most clearly in myrrh resin and in the herbs and spices that contain it, such as celery seed and mint. Myrrh oil, used in some balms and incense, is a rich source. Its warm, slightly spicy smell means it is also used in perfumery. Research Key Studies The review by Nuutinen (2018) and wider research on the elemene family describe the laboratory interest in how these terpenes affect tumour cells. The chemistry of gamma-elemene is recorded in public databases (National Center for Biotechnology Information, 2025). Human evidence for gamma-elemene itself remains very limited. PreviousBeta-Caryophyllene NextCaryophyllene-oxide Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Gamma Elemene first appeared on PatientsCann UK®.</p>

α-Terpineol – PatientsCann UK Skip to main content Back to Terpenes Guide α-Terpineol alpha-Terpineol pronounced: ter-PIN-ee-ol A gentle flowery, piney scent like lilac. Linked to calm and sleep, and common in soaps and lotions. Oxygenated monoterpene Boiling point: 218°C Terpene type Oxygenated monoterpene Boiling point 218°C Primary aroma Floral Key effect Calming Aroma profile How it Smells The aroma of α-Terpineol is described as: FloralLilacPineySweetHerbal Found naturally in: Lilac, pine, cajeput oil, petitgrain, cardamom, marjoram Effects Linked Effects CalmingSleep supportAnti-inflammatory These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is α-Terpineol? Alpha-terpineol is a soft, flowery terpene with a smell often compared to lilac, with a gentle piney background. It is found in lilac flowers, in pine, and in cardamom, and it is one of the smells people find most pleasant and relaxing. It carries an oxygen atom in its structure, which gives it that rounded, almost soapy floral smell. This is why it is used so widely in cosmetics (Booth and Bohlmann, 2019). Effects in detail What the Research Says Among the things studied about alpha-terpineol, its calming and sleep-supporting quality stands out. In animal studies it has shown a sedative-like effect, and it has also been looked at for easing swelling and fighting germs (Nuutinen, 2018). These effects are seen mostly in the laboratory. They fit the relaxed feeling many people describe, but they are not yet proven in human trials. Everyday sources Where You Find it in Daily Life You meet alpha-terpineol in lilac blossom, in pine, and in many flavours and fragrances. It is one of the most common terpenes in soaps, lotions and perfumes because of its pleasant floral smell. It is also used to give a soft, sweet note to some foods and drinks. Research Key Studies Nuutinen (2018) reviewed the evidence on alpha-terpineol, describing its calming effect in animal studies and its anti-inflammatory and germ-fighting activity. Its possible part in the entourage effect has also been discussed (Russo, 2011). Its chemistry is recorded in public databases (National Center for Biotechnology Information, 2025). PreviousFenchol NextAlpha-Bisabolol Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Alpha Terpineol first appeared on PatientsCann UK®.</p>

Fenchol – PatientsCann UK Skip to main content Back to Terpenes Guide Fenchol alpha-Fenchol, Fenchyl alcohol pronounced: FEN-kol A camphor and lemon scent from fennel and basil. Studied as a mild stimulant and germ-fighter. Oxygenated monoterpene Boiling point: 201°C Terpene type Oxygenated monoterpene Boiling point 201°C Primary aroma Camphor Key effect Germ-fighting Aroma profile How it Smells The aroma of Fenchol is described as: CamphorPineySweetLemonEarthy Found naturally in: Fennel, basil, nutmeg, aniseed, cedar, mugwort Effects Linked Effects EnergisingFights germsAntioxidant These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Fenchol? Fenchol, sometimes called fenchyl alcohol, is the terpene that gives basil much of its sweet, slightly camphor-like smell. It also has a clean, lemony piney note and is a big part of the scent of fennel. Like cineole, fenchol carries an oxygen atom, which puts it in the group called alcohols. This gives it a softer, rounder smell than the pure pine terpenes (Booth and Bohlmann, 2019). Effects in detail What the Research Says Early laboratory research has looked at fenchol as a mild stimulant and as a substance that fights germs (Nuutinen, 2018). More recently, scientists have become interested in how fenchol behaves in the gut and brain, although this work is at a very early stage. As with most terpenes, the human evidence is still thin, so these findings are best seen as clues for future research. Everyday sources Where You Find it in Daily Life You meet fenchol most strongly in fresh basil and in fennel. It also appears in nutmeg, in aniseed, and in cedar wood. Tearing a basil leaf releases a clear burst of it. Its fresh, sweet smell means it is used in perfumes and in some flavourings. Research Key Studies Nuutinen (2018) gathered the laboratory studies on fenchol, noting its mild stimulant and germ-fighting activity in cell and animal tests. Its chemical details are recorded in public databases (National Center for Biotechnology Information, 2025). Careful human research has not yet been done. Previous1,8-Cineole Nextα-Terpineol Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Fenchol first appeared on PatientsCann UK®.</p>

1,8-Cineole – PatientsCann UK Skip to main content Back to Terpenes Guide 1,8-Cineole Eucalyptol pronounced: SIN-ee-ol The strong, fresh smell of eucalyptus. Often used to help clear the airways and sharpen focus. Oxygenated monoterpene Boiling point: 176°C Terpene type Oxygenated monoterpene Boiling point 176°C Primary aroma Eucalyptus Key effect Focus Aroma profile How it Smells The aroma of 1,8-Cineole is described as: EucalyptusFreshCoolingMintyCamphor Found naturally in: Eucalyptus, rosemary, sage, bay leaves, tea tree, mugwort Effects Linked Effects Sharpens focusEases breathingAnti-inflammatory These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is 1,8-Cineole? 1,8-cineole, also called eucalyptol, is the terpene behind the strong, fresh smell of eucalyptus. It has a cool, clearing quality that many people know from chest rubs and cold remedies. It also appears in rosemary, sage and bay leaves. Unlike the pure pine or citrus terpenes, cineole carries an oxygen atom in its structure, which is why it smells so sharp and clean (Booth and Bohlmann, 2019). Effects in detail What the Research Says Cineole is one of the better-studied plant terpenes. Research suggests it may help open the airways and ease breathing, and it is widely used in cough and cold products for this reason (Nuutinen, 2018). Some studies have also looked at whether it may help with focus and clear thinking, and at its anti-inflammatory effects. Even with this longer history, most careful studies are small, so it should not be seen as a treatment on its own. Everyday sources Where You Find it in Daily Life You meet cineole in eucalyptus and tea tree oils, in fresh rosemary and sage, and in bay leaves. It is the main active smell in many vapour rubs, throat sweets and mouthwashes. A word of care: eucalyptus oil is strong and should never be swallowed neat, especially by children. Research Key Studies Nuutinen (2018) reviewed the evidence on cineole, including its use for easing breathing and its anti-inflammatory activity. Its role in the entourage effect alongside cannabinoids has also been discussed (Russo, 2011). Its chemistry, including the oxygen in its structure, is recorded in public databases (National Center for Biotechnology Information, 2025). Previousβ-Pinene NextFenchol Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Cineole first appeared on PatientsCann UK®.</p>

β-Pinene – PatientsCann UK Skip to main content Back to Terpenes Guide β-Pinene beta-Pinene pronounced: BAY-tuh PY-neen A fresh, cooling pine scent. The partner of alpha-pinene, studied for mood, worry and memory. Monoterpene Boiling point: 166°C Terpene type Monoterpene Boiling point 166°C Primary aroma Piney Key effect Mood support Aroma profile How it Smells The aroma of β-Pinene is described as: PineyFreshWoodyCoolingResinous Found naturally in: Rosemary, basil, dill, parsley, hops, pine, cumin Effects Linked Effects Lifts moodEases worryHelps memory These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is β-Pinene? Beta-pinene is one of the two pine terpenes, the other being alpha-pinene. It smells fresh and piney with a cool, almost minty lift. It is found in rosemary, basil, dill and parsley, as well as in pine trees themselves. It is a light monoterpene, so it gives off that clean, woodland smell quickly. In cannabis the two pinenes often appear together and shape the bright, herbal top of the aroma. Effects in detail What the Research Says Research on the pinenes suggests they may support mood and help ease feelings of worry, and may have a small effect on memory and alertness (Weston-Green et al., 2021). Beta-pinene has also been studied as a substance that may help open the airways and calm swelling (Nuutinen, 2018). Most of this work is in animals or cells. It points in a hopeful direction but does not yet prove benefit in people. Everyday sources Where You Find it in Daily Life You meet beta-pinene every time you cook with rosemary, basil, dill or parsley. It is also in hops, in cumin, and of course in pine forests. Rubbing a sprig of fresh rosemary releases a strong dose of it. Its clean pine smell makes it common in cleaning products and air fresheners. Research Key Studies A 2021 review by Weston-Green and colleagues looked at pinene and linalool as possible terpene-based medicines for brain health, gathering the early evidence on mood, worry and memory. Nuutinen (2018) also describes beta-pinene’s airway and anti-inflammatory effects, and its chemistry is recorded in public databases (National Center for Biotechnology Information, 2025). PreviousAlpha-Pinene Next1,8-Cineole Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Weston-Green, K. et al. (2021) ‘A review of the potential use of pinene and linalool as terpene-based medicines for brain health’, Frontiers in Psychiatry, 12, 583211. doi: 10.3389/fpsyt.2021.583211. Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Beta Pinene first appeared on PatientsCann UK®.</p>

α-Terpinene – PatientsCann UK Skip to main content Back to Terpenes Guide α-Terpinene alpha-Terpinene pronounced: AL-fuh ter-PIN-een A woody, citrus terpene with a medicinal edge. Best known as a strong natural antioxidant. Monoterpene Boiling point: 174°C Terpene type Monoterpene Boiling point 174°C Primary aroma Woody Key effect Antioxidant Aroma profile How it Smells The aroma of α-Terpinene is described as: WoodyCitrusMedicinalHerbalFresh Found naturally in: Marjoram, cumin, tea tree, allspice, juniper, coriander Effects Linked Effects AntioxidantAnti-microbialAnti-fungal These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is α-Terpinene? Alpha-terpinene is a terpene that smells woody and citrusy with a slightly sharp, medicinal note. It is one of the main parts of tea tree oil and gives marjoram and cumin some of their warm, herby smell. It is a light monoterpene and a close cousin of gamma-terpinene. The two often appear together in the same plants. Effects in detail What the Research Says Alpha-terpinene is one of the strongest plant antioxidants found in the laboratory. It is very good at mopping up free radicals, the harmful particles that can damage cells (Nuutinen, 2018). It is also studied for fighting germs and fungus. Because it reacts so readily with oxygen, it can change over time once a plant oil is opened. This is normal, and it is why fresh oils smell brightest. Everyday sources Where You Find it in Daily Life You meet alpha-terpinene most strongly in tea tree oil, which is used in many skincare products. It is also in the herb marjoram, the spice cumin, in allspice, and in juniper. Its clean, slightly medicinal smell means it turns up in soaps, mouthwashes and household cleaners. Research Key Studies Nuutinen (2018) reviewed the laboratory evidence on alpha-terpinene, highlighting its powerful antioxidant activity and its germ-fighting and fungus-fighting effects in cell tests. Its chemistry is recorded in public databases (National Center for Biotechnology Information, 2025). The human evidence is still at an early stage. PreviousΔ-3-Carene NextAlpha-Pinene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Alpha Terpinene first appeared on PatientsCann UK®.</p>

Δ-3-Carene – PatientsCann UK Skip to main content Back to Terpenes Guide Δ-3-Carene Delta-3-Carene, 3-Carene pronounced: KAIR-een A sweet, piney, citrus scent from pine and cedar trees. Studied for calming and for excess fluid. Monoterpene Boiling point: 169°C Terpene type Monoterpene Boiling point 169°C Primary aroma Piney Key effect Calming Aroma profile How it Smells The aroma of Δ-3-Carene is described as: PineySweetCitrusCedarEarthy Found naturally in: Pine, cedar, rosemary, basil, bell pepper, cypress Effects Linked Effects CalmingBone supportDries excess fluid These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Δ-3-Carene? Delta-3-carene is a terpene with a sweet, piney smell and a hint of citrus and damp earth. It is found in pine and cedar trees, in rosemary and basil, and even in bell peppers. It is a light monoterpene, so its fresh, resinous scent lifts off quickly. In cannabis it adds to that classic forest-like smell that many people enjoy. Effects in detail What the Research Says In animal studies, delta-3-carene has shown a calming, sedative-like quality (Nuutinen, 2018). Researchers have also explored whether it may help dry up extra fluid in the body, and some early work has looked at its possible role in bone health. These are early laboratory findings. One thing to note is that, in large amounts, carene can be drying and may irritate the eyes or throat, which is why balance matters. Everyday sources Where You Find it in Daily Life You will find delta-3-carene in pine and cedar forests, in fresh rosemary and basil, in cypress, and in sweet bell peppers. Pine and cedarwood essential oils are rich in it. Its piney, woody smell makes it popular in cleaning products and air fresheners that aim for a fresh-forest scent. Research Key Studies The review by Nuutinen (2018) summarised the laboratory evidence on delta-3-carene, including its calming effect in animal tests and early interest in bone health. Its chemical make-up is listed in public databases (National Center for Biotechnology Information, 2025). As with other terpenes, careful human research is still needed. PreviousLimonene Nextα-Terpinene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. National Center for Biotechnology Information (2025) PubChem Compound Database. Bethesda: U.S. National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov (Accessed: 11 June 2026). Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 11 June 2026).

<p>The post Delta 3 Carene first appeared on PatientsCann UK®.</p>